Medical devices with managed biodegradation
Medical implants with controlled degradation features, like confinement layers and composition gradients, address the issue of harmful degradation products by managing the degradation process, reducing host harm and potentially eliminating surgical removal.
Patent Information
- Application Number
- JP2024139962
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2016-06-23
- Filing Date
- 2024-08-21
- Publication Date
- 2024-11-08
- Estimated Expiration
- 2037-06-23
AI Technical Summary
Existing medical implants that degrade within the host can cause harm due to undesirable degradation products, necessitating surgical removal or long-term presence, which may be harmful or unnecessary.
Medical implants are designed with physical or chemical features that manage degradation, such as confinement layers, defects, composition gradients, or heterogeneities, to control the degradation process and minimize harm to the host.
The controlled degradation of medical implants reduces harm to the host by managing the timing, location, and dispersion of degradation products, potentially eliminating the need for surgical removal and ensuring safe implant presence.
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims the benefit under 35 USC § 119(e) of U.S. Provisional Patent Application No. 62 / 354,099, filed June 23, 2016, the entire disclosure of which is incorporated herein by reference.
[0002] FIELD OF THEINVENTION The present invention relates generally to biodegradable medical implants and their uses. [Background technology]
[0003] Some medical implants only need to be present in the host for a limited period of time. After that period, the implant can be physically removed, which often requires further surgical intervention. Alternatively, the implant may be left in place indefinitely. This option serves the purpose when the long-term presence of the implant is not detrimental and when a permanent implant is required for a particular procedure. Alternatively, the implant may be formed from a bioabsorbable material. Bioabsorbable materials degrade and / or become absorbable within the host, and their components and their metabolic products are excreted in time. Although bioabsorbable implants are increasingly desired by health care providers, they may have undesirable consequences, such as the host not being able to tolerate the degradation products. Summary of the Invention [Problem to be solved by the invention]
[0004] There is a need in the art for medical implants that do not cause harm to the host upon degradation, or at least cause reduced harm to the host upon degradation.The present invention is directed to filling that need. [Means for solving the problem]
[0005] overview The present disclosure, in one aspect, is directed to medical implants that degrade within a host, where the degradation is managed to occur in a manner that is specifically desired due to physical or chemical characteristics built into the implant. For example, the implant may include a containment layer that surrounds all or a portion of the implant, where the containment layer is constructed to degrade the implant in a manner different than it would degrade in its absence. As another example, the implant may purposely include defects that are particularly vulnerable to degradation, where these defects provide sites where degradation will occur preferentially relative to other sites of the implant. In one embodiment, the defects do not provide any functional benefit to the device, e.g., the defects do not reinforce or make the device work better, but are simply present to affect the degradation profile of the implant. As yet another example, the implant may include a composition vector, meaning that the composition of the implant varies along a dimension of the implant, e.g., along its length. The different compositions have correspondingly different degradation susceptibility under the conditions to which the implant is exposed within the host. This approach allows, for example, one end of the implant to be caused to degrade before the other end degrades. As a final example, an implant may include compositional heterogeneity, where the site of heterogeneity is more or less susceptible to degradation than adjacent homogeneous sites of the implant. For example, an implant may include particles dispersed in a polymer, where the polymer is homogeneous and the particles provide a heterogeneity that is more susceptible to degradation than the polymer, or act as initiation sites for degradation of the polymer. These are examples of controlled degradation according to the present disclosure, whereby medical implants that degrade within a host are constructed in a controlled manner such that degradation occurs in a manner that is specifically desired due to physical or chemical characteristics that have been engineered into the implant by the construction of the implant.
[0006] In one exemplary embodiment, the present invention is directed to a medical implant comprising a containment layer at least partially encasing a medical device, said medical device being at least partially degradable when said implant is implanted into a host, said containment layer being either non-biodegradable or biodegradable, but where the containment layer is biodegradable it degrades slower than the portions it surrounds.
[0007] Optionally, the containment layer serves as a container for fragments of the medical device that form upon degradation of the medical device. Optionally, the device provides structural support within the host, where also optionally, the device is a stent, such as an intraureteral stent. The containment layer may be a coating on the medical device, where the coating is optionally hydrophilic. If the coating is biodegradable, it should have a slower degradation rate than the medical device that is enveloped by the coating.
[0008] In another exemplary embodiment, the present disclosure provides a medical implant including a containment layer at least partially encapsulated by a medical device, wherein said containment layer at least partially encapsulates a hollow core of said medical device, said medical device being at least partially biodegradable when said implant is implanted in a host, said containment layer being either non-biodegradable or biodegradable, wherein said containment layer provides a barrier between the degradation products of the medical device that form during biodegradation of said medical device and the hollow space of said medical device. Alternatively, the containment layer may completely encapsulate a medical device by covering the inner and outer structures of a stent, e.g., a ureteral stent.
[0009] The containment layer manages the degradation of the device, which may also include migration of the device, e.g., excretion of the device. In one option, the containment layer may be a coating located on or within the medical device. In another option, the containment layer may be a mesh located on or within the medical device. The containment layer may cover only a portion of the medical device, for example, the end of a tubular medical device may have a cap that acts as a containment layer.
[0010] This disclosure describes several medical devices, however any of the described medical devices may be modified to exhibit managed degradation by the means disclosed herein. For example, any of these medical devices may be modified to have selectively degraded polymer components to contain slits or to have molecular weight gradients, thereby providing a managed device degradation profile to occur in a manner that is particularly favorable for the physical or chemical characteristics incorporated into the implant according to the present disclosure.
[0011] This brief summary is provided to introduce certain concepts in a simplified form that are more fully described below in the Detailed Description. Unless expressly stated otherwise, this brief summary is not intended to identify key or essential features of the claimed subject matter, nor is it intended to limit the scope of the claimed subject matter.
[0012] The details of one or more embodiments are set forth in the following specification. Features illustrated or described with respect to one exemplary embodiment may be combined with features of other embodiments. Thus, any of the various embodiments described herein may be combined to provide further embodiments. Aspects of the embodiments may be modified, if necessary, to employ concepts of various patents, applications, and publications as set forth herein to provide still further embodiments. Other features, objects, and advantages will become apparent from the specification and claims.
[0013] Detailed Description The present invention can be more easily understood by referring to the following detailed description of the preferred embodiments of the present invention and the examples contained herein. It should be understood that the technical terms used in this specification are merely for the purpose of describing specific embodiments and are not intended to be limiting. Furthermore, it should be understood that the technical terms used in this specification are given their conventional meanings as known in the relevant technical field unless otherwise defined in this specification. The headings used in this specification are merely used to facilitate the reader's review and should not be interpreted as limiting the scope of the present invention or the claims in any way.
[0014] As used in this document, including the claims, the singular forms "a," "an," and "the" include plural references unless indicated otherwise. For example, "a" polymer includes one or more polymers. As another example, "a" layer refers to one or more layers.
[0015] "Degrade" means that in a degradable medical device, the medical device disintegrates or deteriorates, either in a chemical or structural sense, when implanted in a host at a location within the host for which the device is intended. For example, a device that breaks into pieces (e.g., it breaks into halves or it breaks into multiple pieces) is a structurally degraded device. If the device softens when implanted, then the device degrades in a structural sense. If part or all of the device dissolves in the body fluid with which the device is in contact, then the device degrades chemically. Chemical degradation also includes the presence of degradation reactions such as hydrolysis, oxidation, and enzymatic bond cleavage. An absorbable or bioabsorbable medical device is a device that degrades within the host. A degradable implantable medical device refers to an implantable medical device that is intended by the manufacturer and / or health care provider to have a desirably limited life span within the host. In other words, the manufacturer and / or health care provider has manufactured and / or selected the device, in part, because the device should naturally degrade within the host and not become a permanent fixture within the host.
[0016] "Degradation profile" refers to a description of how an implant degrades. The degradation profile can provide a time course of the implant degradation as well as a geometric description of the degradation during the time course. For example, an implant can have a degradation profile in which the implant degrades from top to bottom along its length over the course of a given number of days.
[0017] "Host" refers to a mammal, such as humans, dogs, cats, and livestock. A host may also be referred to as a patient or subject.
[0018] Implantable "medical device", as used herein, refers to a device, such as an instrument or apparatus, that is intended to be implanted into the body of a host by a health care provider. A medical device provides a medical (e.g., as opposed to merely cosmetic) purpose or benefit in that it improves the health of the host by one or more of the diagnosis, prevention, treatment, or cure of an undesirable medical condition, such as a disease. A medical device may be an adjunct device that does one or more of the following: assists the performance of a parent medical device by enabling or encouraging the parent medical device to function according to its intended use; complements the performance of a parent device by adding new functions or new methods of use of the parent device without changing the intended use of the parent device; or enhances the performance of a parent device by enabling the device to perform its intended use more safely or effectively. The medical device does not fulfill its purpose merely through chemical action in the body, and the medical device does not fulfill its purpose when metabolized.
[0019] In one aspect, the medical device is used in maintaining or creating patency of a conduit, e.g., a duct or blood vessel, within a host. Exemplary ducts and blood vessels are found, for example, along the gastrointestinal (GI) tract of a host, e.g., the esophagus, intestine (including the transverse colon, descending colon, ascending colon, sigmoid colon, and small intestine (wherein the small intestine includes the duodenum, jejunum, and ileum), cecum, and rectum). In one embodiment, the medical implant is designed to be implanted in the ureter, i.e., the tube that carries urine from the kidney to the bladder. In another embodiment, the medical implant is designed to be implanted in the urethra, i.e., the tube that transports urine from the bladder to the outside of the host. Other exemplary ducts and blood vessels are found in organs such as the heart, pancreas, prostate, and kidney. Another location where a duct or blood vessel exists within a host and where a medical implant may be implanted according to the present disclosure is the milk duct, which transports milk from the lobule (milk producing gland) to the nipple. Other locations for medical implants include the ear and sinuses.
[0020] In one embodiment, the medical device is formed at least in part from one or more of a thermoplastic polymer, a thermosetting polymer, or an elastomeric polymer. In one embodiment, the medical device is sterile. In one embodiment, the medical device is intended to be fully implanted into the host, i.e., fully subcutaneous to the host, as opposed to, for example, a hearing aid placed in the ear, a dental prosthesis placed in the host's mouth, or a contact lens placed on the host's eye. In one embodiment, the implantable medical device is intended to be implanted into a body passageway, such as a tube or blood vessel. Examples of implantable medical devices, which may also be degradable, include stents, shunts, sutures, and surgical meshes. Implantable medical devices are also described in the following patent documents: U.S. Patent Nos. 8,753,387; 8,101,104; 7,594,928; and U.S. Patent Application No. 2014 / 0288636.
[0021] "Medical implant" refers to a device of the present invention that includes both a degradable implantable medical device and a containment layer disposed adjacent to at least a portion of the medical device.
[0022] Briefly, the present invention provides a medical implant comprising a bioabsorbable medical device and a containment layer therefor. During the process of bioabsorption within the host, the medical device degrades. To manage the degradation process, e.g., the time of degradation, the type of degradation, the extent of degradation, and the movement of the degraded medical device (including its portion within the host), the medical implant comprises one or more containment layers. The containment layer can, for example, prevent degradation fragments from dispersing within the host and potentially damaging nearby tissues and / or organs. In one embodiment, the containment layer at least partially, and optionally completely, encapsulates the medical device. When the medical device degrades into fragments, the containment layer encapsulates the collapsing medical device and maintains sufficient structural integrity to hold, or at least helps to hold, the fragments together in the containment space. The containment layer can affect and induce the evacuation of the medical device, including any fragments formed therefrom, from the host.
[0023] In one aspect, the present disclosure provides degradable medical devices. Below are described degradable compositions and / or components thereof that can be used to form medical devices, as well as containment layers that can be part of or added to the medical devices.
[0024] In general, the medical device and containment layer may be fabricated from biostable or non-biostable materials, where non-biostable materials are also referred to herein as degradable materials and may be known in the art as either biodegradable, absorbable or bioabsorbable, erodible or bioerodible, soluble or biosoluble. Degradable polymers are capable of being completely eroded or absorbed when exposed to bodily fluids such as blood, and may be gradually resorbed, absorbed, and / or excreted by the body. Some degradable materials become absorbable due to chemical degradation that occurs to the material when exposed to bodily fluids, such as may be found in the vascular environment of the host. Chemical degradation refers to the breakdown of a material due to chemical reactions between the material and the bodily fluid or substances within the bodily fluid. Chemical degradation may be the result of hydrolysis, oxidation, enzymatic degradation, and / or metabolic processes, etc. Chemical degradation may result in, for example, a reduction in molecular weight, deterioration of mechanical properties, and loss of mass due to erosion. Mechanical properties may correspond to the strength and modulus of the material. Degradation of the mechanical properties of a material reduces the ability of a medical device fabricated therefrom to function optimally within a host. For example, if the device is a stent, the stent provides mechanical support within the blood vessel that decreases as it degrades. In addition, some degradable materials are water soluble. Water soluble materials refer to materials that are capable of dissolving in water in addition to, or even in the absence of, chemical degradation of the material.
[0025] In one embodiment, the degradable medical device or containment layer is formed in whole or in part from a degradable organic polymer. The organic polymer may be, for example, a thermoplastic polymer or a thermosetting polymer or an elastomeric polymer. The organic polymer may be a copolymer, where the copolymer is made from two or more different monomers to provide properties not readily available from a homopolymer. The organic polymer may be a mixture of one or more different polymers, for example, one or more different organic polymers. Thus, various degradable organic monomers as specified herein may be used together to make homopolymers or copolymers, and various organic polymers as specified herein may be used in combination to make mixtures. The medical device of the present disclosure is degradable and therefore contains some degradable components. In one embodiment, the medical device is made entirely from degradable materials, and therefore the medical device is completely degradable. In another embodiment, the medical device is made predominantly from degradable materials, and therefore at least 50% by weight of the medical device is degradable. In another embodiment, the medical device is made from both degradable and biostable materials, and therefore less than 100% of the medical device is degradable. In various embodiments, up to 100%, or up to 95%, or up to 90%, or up to 85%, or up to 80%, or up to 75%, or up to 70%, or up to 65%, or up to 60%, or up to 55%, or up to 50%, or up to 45%, or up to 40%, or up to 35%, or up to 30%, or up to 25% of the medical device is made from degradable materials, these percentage values being weight % based on the weight of the implantable medical device.
[0026] Examples of degradable polymers that can be used to fabricate the containment layer or medical device of the present disclosure include poly(alpha-hydroxy acid) polymers and copolymers, such as polymers and copolymers of glycolide, including polyglycolide (PGA), poly(glycolide-co-lactide) (PGLA), and polyglycolide-co-trimethylene carbonate (PGA / TMC); polymers and copolymers of polylactide (PLA), including poly-L-lactide (PLLA), poly-D-lactide (PDLA), poly-DL-lactide (PDLLA), poly(lactide-co-tetramethylene glycolide), poly(lactide-co-trimethylene carbonate), poly(lactide-co-delta-valerolactone), poly(lactide-co-epsilon-caprolactone), poly(glycine-co-DL-lactide), and poly(lactide-co-ethylene oxide); polydioleate (POE) ... Poly(β-hydroxybutyrate) (PHBA) and its copolymers such as poly(β-hydroxybutyrate-co-β-hydroxyvalerate); polygluconates; poly(β-hydroxypropionate) (PHPA); poly(β-dioxanone) (PDS); poly(δ-valerolactone); poly(ε-caprolactone); methyl methacrylate-N-vinylpyrrolidone copolymers; polyesteramides; polyesters of oxalic acid; polydihydropyran; poly(alkyl-2-cyanoacrylate); polyvinyl alcohol (PVA); polypeptides; poly(β-maleic acid) (PMLA); poly(β-alkanoic acids); poly(ethylene oxide) (PEO); polyanhydrides, polyphosphoesters, and chitin polymers.
[0027] In one embodiment, the organic polymer is a polyester. For example, the polymer may be a polyester selected from poly(α-hydroxy acid) homopolymers, poly(α-hydroxy acid) copolymers, and blends thereof. Additionally or alternatively, the polyester may be selected from polyglycolide, poly-L-lactide, poly-D-lactide, poly-DL-lactide, and blends thereof. The polyester may be selected from polylactide (PLA) polymers and copolymers, including poly-L-lactide (PLLA), poly-D-lactide (PDLA), poly-DL-lactide (PDLLA).
[0028] In one embodiment, the organic polymer is semi-crystalline or can be formed as fibers, or is both semi-crystalline and fiber-forming. In one embodiment, the containment layer is made with an organic polymer that is at least one of semi-crystalline and fiber-forming. In one embodiment, the degradable stent is made with an organic polymer that is both semi-crystalline and fiber-forming. To further make the organic polymer rapidly degradable, glycolide may be used as a monomer or one of the monomers used to form the organic polymer. Paradioxane (PDO) is another suitable monomer for forming rapidly degradable organic polymers, where the corresponding homopolymer is known as poly(PDO). Poly(PDO) generally degrades glycolide-based polymers more slowly, therefore, to make an ultra-rapidly degradable organic polymer, the monomer feed is preferably rich in glycolide.
[0029] In one embodiment, the organic polymer has a multiaxial structure, while in another embodiment, the organic polymer is linear. The multiaxial structure may be part of the organic polymer, for example, it may be present in a block of a block copolymer. Another option is for the organic polymer to be a segmented multiaxial, semi-crystalline and fiber-forming, and glycolide-based, to ensure rapid degradation. Yet another option is to use linear copolymers for either or both: diblock, triblock, pentablock, where the central block is amorphous and the other blocks are semi-crystalline, except for the pentablock, which may be a PEG with an amorphous segment connected to the outer crystalline segments (forming a symmetric pentablock polymer, i.e., polyether-ester; all other polymers can be said to be aliphatic polyesters). Linear block copolymers can also produce polymers that can be oriented after fiber formation to create alternating patterns with different crystal structures and percentages in the fiber, without any amorphous blocks in all cases, so that there is a slight difference in the degradation profile of the alternating blocks that form the fiber (when the fiber is oriented, horizontal stripes of crystalline regions form, aligning the blocks that comprise the polymer chains). Alternatively, they can replace non-block linear copolymers. In one embodiment, these organic polymers are used to form fibers, and these fibers are used to form the containment layer. In another embodiment, these organic polymers are not formed as fibers, but are used to form the containment layer, for example, by simply spraying the polymer solution onto the medical device or by dip coating.
[0030] The containment layer or medical device may be made from a base polymer that is amorphous, compliant and elastomeric. It can also be crystallized, but too much crystallinity generally reduces the compliant nature of the polymer. If a more crystalline material is selected for use, it may be advisable to incorporate a plasticizer, such as PEG, into the layer to reduce the final crystallinity of the layer when applied to the medical device. As previously mentioned, the polymer may be a multiaxial or linear, block or segmented or random polymer. For a flexible and compliant containment layer, the organic polymer may be minimally crystalline or amorphous.
[0031] The organic polymer may be made from a prepolymer and from the endograft if it is a block copolymer or cannot be made from a prepolymer. In one embodiment, one or more monomers selected from caprolactone, trimethylene carbonate, and / or l-lactide are used to form the organic polymer for the containment layer to extend the degradation time frame beyond that of the medical device.
[0032] Suitable degradable organic polymers other than polyesters include polyether-esters, polyether-ester-urethanes (bioresorbable urethanes), polyether-urethanes and polyether-urethane-ureas, the above examples exhibiting very slow and generally incomplete degradability.
[0033] In various embodiments, the medical device and / or containment layer are made from any of the following polymers: MG-5 (Poly-Med, Anderson, SC) with >65% glycolide in the endograft is a semi-crystalline multiaxial block copolyester made in a two-step reaction from an amorphous prepolymer and a crystalline endograft. MG-9 (Poly-Med, Anderson, SC) with >80% glycolide is a semi-crystalline multiaxial block copolyester made in a two-step reaction from an amorphous prepolymer and a crystalline endograft. A semi-crystalline multiaxial segmented copolyester made in a one-step reaction (no prepolymer). A semi-crystalline linear block copolyester made in a two-step reaction from an amorphous prepolymer and a crystalline endograft. A triblock copolymer with a crystalline endograft. A diblock copolymer. A semi-crystalline linear segmented copolyester made in a one-step reaction (no prepolymer). SVG-12 (Poly-Med, Anderson, SC) with an intrinsic viscosity of 1.0 and crystalline end grafts. Multiaxial block copolymers. Polymers made from amorphous prepolymers and amorphous end grafts. Linear block copolymers (triblock, diblock, pentablock). Linear segmented copolymers. Linear random copolymers that are amorphous and therefore both compliant and flexible. The above are merely examples of organic polymers that can be used to make suitable medical devices, parts thereof, or containment layers.
[0034] Another suitable polymer is a mixture comprising (a) a bioerodible polyester network formed by the reaction between reactive species comprising a polyol and a polycarboxylate, at least one of the polyol and the polycarboxylate having three or more functions, and (b) a bioerodible thermoplastic polymer. Optionally, the composition may be further characterized by one or more of the following: the polyol is selected from a non-polymeric diol, a polymeric diol, a non-polymeric triol, and a polymeric triol; the polycarboxylate is selected from a non-polymeric dicarboxylate, a polymeric dicarboxylate, a non-polymeric tricarboxylate, and a polymeric tricarboxylate; the reactive species includes a triol, a tricarboxylate, or both; the reactive species includes (a) a non-polymeric tricarboxylate, and (b) a polyester polyol; the reactive species includes (a) citric acid, and (b) a polycaprolactone diol, a polycaprolactone triol, or both; the bioerodible thermoplastic polymer has a melting point higher than body temperature; the bioerodible thermoplastic polymer has a glass transition temperature lower than room temperature; and the bioerodible thermoplastic polymer is a bioerodible thermoplastic polyester. For example, US Patent Publication No. 20160166739.
[0035] In one aspect, the medical implant of the present disclosure includes a containment layer in addition to the medical device. Both the location of the containment layer relative to the medical device and the properties of the containment layer in terms of physical and chemical properties aid in managing the degradation and / or elimination of the medical implant from the host. In particular, the containment layer acts in part to manage the degradation and / or elimination of the medical implant from the host. The properties of the containment layer should also be selected with the objective of managing the degradation and / or elimination of the containment layer itself from the host.
[0036] The medical device present in the medical implant of the present disclosure is degradable to at least some degree. In other words, the medical device becomes degradable when placed in a host. The degradation can be physical or chemical degradation. Physical degradation refers to a change in the physical or mechanical properties of the medical device. For example, the device may crumble into fragments and thus lose its integrity. As another example, the device may soften and become compliant. As yet another example, the device may absorb liquid and swell. In each of these cases, the device undergoes a change in physical or mechanical properties. Chemical degradation refers to a change in chemical composition. For example, organic polymers from which the device is manufactured may undergo hydrolytic bond scission or enzymatically induced bond scission, thereby reducing the molecular weight. As another example, water-soluble components of the medical device may dissolve in water and remain in the vicinity of the medical device. In each of these examples, chemical degradation results in a change in the chemical description of the medical device. There may also be cases in which the degradation of the medical implant achieves physical as well as chemical degradation simultaneously. In either case, the containment layer of the present disclosure may act partially or fully to affect this degradation. Thus, the properties of the containment layer can be used to manage the degradation and / or expulsion of the medical implant from the host.
[0037] In one aspect, the containment layer provides a physical barrier between the host tissue and the medical device. For example, such a barrier is useful when the device degrades by breaking down into fragments, and it is desired to manage the dispersion or diffusion of those fragments. For example, in one embodiment, the containment layer may be relatively long-lasting compared to the medical device, so that when the medical device breaks down into fragments, the containment layer maintains sufficient structural integrity to retain those fragments within the containment layer. Such a containment layer is useful when the medical device is implanted in the kidney, and it is undesirable for fragments from the medical device to come into contact with the inside of the kidney and calcify. In a related embodiment, the containment layer is again relatively long-lasting compared to the medical device, which is an esophageal stent. In this case, if the esophageal stent breaks down into fragments, the containment layer located within and surrounding the luminal wall of the stent will prevent those fragments from passing to the stomach. Thus, in both instances, the containment layer effectively restricts the movement of fragments of the medical device.
[0038] In another aspect, the containment layer provides a physical or chemical barrier between the host's degradation-inducing fluids and the medical device. This layer can be used to affect the spatial and temporal degradation of the medical device. For example, in one embodiment, the containment layer is a discontinuous layer such that the layer covers some, but not all, of the medical device. In this situation, the containment layer effectively acts as a barrier between the medical device and the host's degradation-inducing bodily fluids, thereby limiting contact between the medical device and the bodily fluids. The containment layer allows the exposed portions of the medical device to degrade more quickly than the non-exposed portions of the medical device. In this way, the containment layer is used to manage when the device degrades first.
[0039] In another embodiment, a graded containment layer is used to manage the spatial and temporal degradation and / or excretion of the medical device. For example, the medical device may have a single coating layer on a first portion of the device, a double coating layer on a second portion of the device, and a triple coating layer on a third portion of the device. Assuming that the composition of the coating layers is the same at each location, the first portion of the medical device will begin to degrade before the second and third portions of the device. Depending on the relative thickness of each portion, the first portion may significantly degrade and be excreted from the host, while the second and third portions of the device remain significantly more intact. The degradation and excretion of the first portion of the medical device allows increased access of bodily fluids to the second portion of the medical device, with the consequence that the second portion will undergo degradation, even though the second portion may still be covered by the containment layer. After the second portion of the device undergoes degradation and excretion, the degradation and excretion of the third portion of the device occurs. In this example, the containment layer manages the rate at which the various portions of the medical device degrade and are excreted from the host. It is noted, however, that the containment layer may also serve to manage the dispersion or diffusion of those fragments, i.e., to limit the movement of those fragments within the host.
[0040] The medical implant, including the medical device itself and / or its containment layer, may include a therapeutic agent. The amount of therapeutic agent incorporated into the implant depends on the nature of the implant, the actual therapeutic agent, and the subject's condition, etc. The amount can be easily determined by one skilled in the art. Exemplary therapeutic agents include antithrombotic agents, antiproliferative agents, anti-inflammatory agents, anti-migratory agents, antineoplastic agents, mitotic inhibitors, anesthetic agents, and anti-aggregatory agents. Further suitable therapeutic agents include agents that affect the production and organization of the extracellular matrix, vascular cell growth (either promoters or inhibitors), cholesterol lowering agents, vasodilators, and agents that interfere with endogenous vasoactive mechanisms.
[0041] In various embodiments of the present invention, the medical device may be a ureteral stent. The medical device, e.g., the ureteral stent, may be designed to release one or more drugs, where representative examples of drugs include one or more suitable members of the following: alpha-adrenergic blockers, analgesics, anti-cancer drugs, antineoplastic drugs, anti-inflammatory drugs, antibacterial drugs, anti-proliferative drugs, anticonvulsants, beta-adrenergic agonists, bronchodilators (e.g., for muscle relaxant properties), calcium channel blockers, corticosteroids, anesthetics, narcotic analgesics, nitric oxide donors, nitric oxide releasing compounds, non-narcotic analgesics, prostaglandins, and combinations thereof, among others.
[0042] Further representative examples of drugs include one or more of the following: angiogenesis inhibitors, 5-lipoxygenase inhibitors and antagonists, chemokine receptor antagonists CCR (1, 3, and 5), cell cycle inhibitors, cyclin-dependent protein kinase inhibitors, EGF (epidermal growth factor) receptor kinase inhibitors, elastase inhibitors, factor Xa inhibitors, farnesyltransferase inhibitors, fibrinogen antagonists, guanylate cyclase stimulators, heat shock protein 90 antagonists, HMGCoA reductase inhibitors, hydroorotate dehydrogenase inhibitors, IKK2 inhibitors, IL-1, ICE and IRAK antagonists, IL-4 agonists, immunomodulators, inosine monophosphate dehydrogenase inhibitors, leukotriene inhibitors, MCP-1 antagonists, MMP inhibitors, NFkappa B Inhibitorsm NO agonists (NF kappa B Inhibitorsm NO agonists). Agonists, P38MAP kinase inhibitors, phosphodiesterase inhibitors, TGFβ inhibitors, TNFa antagonists and TACE inhibitors, tyrosine kinase inhibitors, vitronectin inhibitors, fibroblast growth factor inhibitors, protein kinase inhibitors, PDGF receptor kinase inhibitors, endothelial growth factor receptor kinase inhibitors, retinoic acid receptor antagonists, platelet-derived growth factor receptor kinase inhibitors, fibronogin antagonists, antifungals, bisphosphonates, phospholipase A1 inhibitors, histamine H1 / H2 / H3 receptor antagonists, macrolide antibiotics, GPIIb IIIa receptor antagonists, endothelin receptor antagonists, peroxisome proliferator-activated receptor agonists, estrogen receptor drugs, somatostatin analogs, neurokinin 1 antagonists, neurokinin 3 antagonists, neurokinin antagonists, VLA-4 antagonists, osteoclast inhibitors, DNA topoisomerase ATP hydrolysis inhibitors, angiotensin I converting enzyme inhibitors, angiotensin II antagonists, enkephalinase inhibitors, peroxisome proliferator-activated receptor gamma agonistsInsulin sensitizers, protein kinase C inhibitors, CXCR3 inhibitors, Itk inhibitors, cytosolic phospholipase A2-alpha inhibitors, PPAR agonists, immunosuppressants, Erb inhibitors, apoptosis agonists, lipocortin agonists, VCAM-1 antagonists, collagen antagonists, alpha2 integrin antagonists, TNFalpha inhibitors, nitric oxide inhibitors, and cathepsin inhibitors.
[0043] Examples of alpha-adrenergic blockers include alfuzosin, amosulalol, arotinilol, dapiprazole, doxazosin, ergoloids, fenspiride, idazoxan, indoramin, labetalol, manotepir, mesylate, naftopidil, nicergoline, prazosin, tamsulosin, terazosin, tolazoline, trimazosin, and yohimbine.
[0044] Examples of anesthetics include benzocaine, cocaine, lidocaine, mepivacaine, and novacaine.
[0045] Beta-adrenergic agonists include albuterol, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, denopamine, ephedrine, epinephrine, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, ibopamine, isoetharine, isoproterenol, mabuterol, metaproterenol, methoxyphenamine, oxyfedrine, pirbuterol, prenalterol, procaterol, protokylol, reproterol, rimiterol, ritodrine, salmerterol, soterenol, terbutaline, tretoquinol, tulobuterol, and xamoterol.
[0046] Examples of anti-cancer, anti-proliferative and antineoplastic agents include agents that affect microtubule motility (e.g., colchicine, Epo D, epothilones, paclitaxel, vinblastine, vincristine, etc.), alkyl sulfonates, angiogenesis inhibitors (e.g., angiostatin, endostatin, squalamine, etc.), antimetabolites such as purine analogs (e.g., 6-mercaptopurine or cladribine, i.e., chlorinated purine nucleoside analogs), pyrimidine analogs (e.g., 5-fluorouracil, cytarabine, etc.) and antibiotics (e.g., daunorubicin, doxorubicin, etc.), caspase activators, cerivastatin, cisplatin, ethylenimines, flavopiridol, limus drugs (e.g., everolimus, sirolimus, tacrolimus, zotarolimus, etc.), methotrexate, nitrogen mustards, nitrosoureas, proteasome inhibitors, and suramin.
[0047] Examples of antibacterial agents include benzalkonium chloride, chlorhexidine, nitrofurazone, silver particles, silver salts, metallic silver and antibiotics such as gentamicin, minocycline and rifampin, triclosan.
[0048] Examples of bronchodilators include, inter alia: (a) ephedrine derivatives such as albuterol, bambuterol, bitolterol, carbuterol, clenbuterol, clorprenaline, dioxethedrine, ephedrine, epinephrine, eprozinol, etafedrine, ethylnorepinephrine, fenoterol, formoterol, hexoprenaline, isoetharine, isoproterenol, mabuterol, metaproterenol, n-methylephedrine, pirbuterol, procaterol, protokylol, reproterol, rimiterol, salmeterol, soterenol, terbutaline and tulobuterol; (b) quaternary ammonium compounds such as bevonium methylsulfate; flutropium bromide, ipratropium bromide, oxitropium bromide and tiotropium bromide, (c) xanthine derivatives such as acefylline, acefylline piperazine, ambuphylline, aminophylline, bamifylline, choline theophyllinate, doxofylline, dyphylline, etamiphylline, etophylline, guaithylline, proxyphylline, theobromine, 1-theobromine acetate and theophylline, and (d) other bronchodilators such as fenspiride, medibazine, methoxyphenanime and tretoquinol, as well as combinations and pharma- ceutically acceptable salts, esters and other derivatives of the above.
[0049] Examples of calcium channel blockers include arylalkylamines (including phenylalkylamines), such as bepridil, clentiazen, fendiline, gallopamil, mibefradil, prenylamine, semotiadil, terodiline, and verapamil; benzothiazepines, such as diltiazem; calcium channel blockers, such as bencyclane, etafenone, fantofarone, monotepir, and perheximide, among other calcium channel blockers. dihydropyridine derivatives (including 1,4-dihydropyridine derivatives) such as amlodipine, aranidipine, barnidipine, benidipine, cilnidipine, efonidipine, elgodipine, felodipine, isradipine, lacidipine, lercanidipine, manidipine, nicardipine, nifedipine, nilvadipine, nimodipine, nisoldipine and nitrendipine, piperazine derivatives such as cinnarizine, dotalizine, flunarizine, lidoflazine and lomerizine.
[0050] Examples of corticosteroids include, among others, betamethasone, cortisone, deflazacort, dexamethasone, hydrocortisone, methylprednisolone, prednisolone, prednisone, and triamcinolone, as well as combinations and pharma- ceutical acceptable salts, esters, and other derivatives thereof.
[0051] Examples of nitric oxide donors / releasing molecules include inorganic nitrates / nitrites, such as amyl nitrite, isosorbide dinitrate, and nitroglycerin; inorganic nitroso compounds, such as sodium nitroprusside; sydnonimines, such as linsidomine and molsidomine; NONOates, such as diazeniumdiolates and NO adducts of alkanediamines; S-nitroso compounds, including low molecular weight compounds (e.g., S-nitroso derivatives of captopril, glutathione, and N-acetylpenicillamine) and high molecular weight compounds (e.g., S-nitroso derivatives of natural polymers / oligomers, oligosaccharides, peptides, polysaccharides, proteins, and synthetic polymers / oligomers), as well as the C-nitroso compound L-arginine, N-nitroso compounds, and O-nitroso compounds.
[0052] Examples of prostaglandins and analogs thereof for use in the present disclosure may be selected from suitable members of the following: prostaglandins, such as PGE1 and PGI2, and prostacyclin analogs, such as beraprost, carbacyclin, cyprostene, epoprostenol, and iloprost.
[0053] Examples of narcotic analgesics include, among others, codeine, fentanyl, hydromorphonein, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, propoxyphene, and pentazocine, as well as combinations and pharma- ceutically acceptable salts, esters, and other derivatives thereof.
[0054] Examples of non-narcotic analgesics include analgesics such as acetaminophen, and nonsteroidal anti-inflammatory drugs such as aspirin, celecoxib, diflunisal, diclofenac, etodolac, fenoprofen, flurbiprofen, ibuprofen, ketoprofen, ketorolac, meclofenamate, meloxicam, nabumetone, naproxen, naproxen indomethacin, oxaprozin, piroxicam, salsalate, sulindac, tolmetin, and valdecoxib.
[0055] The medical devices of the present disclosure, such as ureteral stents, may be manufactured to contain and release one or more of these or other therapeutic agents. In addition to the drugs listed herein, pharma- ceutically acceptable salts, esters, and other derivatives of the drugs are also available. The drugs provided herein may be loaded, for example, into the polymeric components of the medical device. If the medical device is a stent, the drug may be incorporated into the coil, the knitted construct adjacent to the coil, or a coating that impregnates the knitted construct. The drug may be incorporated into a coating that is applied onto the medical device.
[0056] Urologically beneficial drugs may be associated with drug-releasing stents in a variety of ways, including, inter alia: (a) loading onto the interior (bulk) of a stent component, e.g., a monofilament coil, or a multifilament knit construct, or onto a coating or sleeve or sheath; (b) binding to a surface of the stent, e.g., the surface of a monofilament coil, or the surface of a multifilament knit construct, or onto a containment layer or sleeve or sheath, where the drug is bound to the surface by either covalent and / or non-covalent interactions (e.g., van der Waals forces, hydrophobic interactions and / or electrostatic interactions, e.g., interactions such as charge-charge interactions, charge-dipole interactions, and dipole-dipole interactions, including hydrogen bonding); (c) application as a coating over all or a portion of the stent or a component thereof; (d) loading onto surface features (e.g., recesses) of the stent or a component thereof; and (e) combinations of the above.
[0057] The amount of urologically beneficial drug associated with the drug-eluting stent should be a therapeutically or prophylactically effective amount, where the amount can range from 1% by weight or less to 2%-5%-10%-25%-50% by weight or more, depending on the particular drug and the desired effect.
[0058] In one embodiment of a medical device containing a drug, the present disclosure provides a medical device for placement in a mammalian body comprising a polymeric matrix forming the device and defining a lumen throughout the device, a matrix comprising polymeric macromolecules and defining spaces between the polymeric macromolecules; a drug contained within at least a portion of the spaces of the matrix; and a material contained within at least a portion of the spaces of the matrix to affect diffusion of the drug out of the polymeric matrix when the medical device is placed in the mammalian body. Optionally, the medical device of the present disclosure may be further characterized by one or more of the following: the polymeric material and the drug each have a molecular weight such that the molecular weight of the drug is less than the molecular weight of the polymeric material; the amount of drug associated with the device is 0.1 to 50 weight percent of the weight of the device; the medical device is a ureteral stent or catheter; the polymeric component comprises ethylene vinyl acetate (EVA); the polymeric component is hydrophobic; at least a portion of the space containing the drug also contains a polymeric material; the drug comprises oxybutynin chloride or ketorolac; the material associated with the drug comprises polyethylene glycol (PEG); the drug is associated with a biodegradable material; the drug is associated with a material that must dissociate before the drug can diffuse from the material out of the polymer matrix; and the polymeric matrix is coated onto the device.
[0059] Thus, the medical device can be used as a vehicle to deliver one or more drugs to the patient's body. Ureteral stents, catheters, and / or other medical devices can be used to deliver drugs by placing the device completely or partially in the patient's body. By using certain materials and drugs in the polymer matrix, the diffusion of the drug out of the matrix can be controlled in a way that was not previously achievable. One or more drugs can thereby be administered to the patient's body at relatively constant therapeutic levels over a sustained period of time (e.g., ranging from days to months).
[0060] A drug delivery medical device according to the present disclosure may be formed in whole or in part of a polymer matrix loaded with a drug and a material that affects the diffusion of the drug out of the matrix when the device is placed in the body of a human or other mammal. The device may be a ureteral stent, a catheter, a dialysis tube, a cannula, a urethral stent, a suture, or other medical device designed for placement (fully or partially) in the body. A device according to the present disclosure may be coated in whole or in part with such a loaded polymer matrix, if desired. For example, a hydrophobic polymer matrix may coat all or a portion of a lead wire, a stent, or a catheter.
[0061] In another embodiment, the present disclosure provides a ureteral stent including an elongate stent body, an expandable retention structure, and a drug release member selected from (i) a sleeve of drug release material disposed on at least a portion of the expandable retention structure, (ii) a sheet of drug release material attached to the expandable retention structure, and (iii) a sheet of drug release material connected to the sleeve of material disposed on at least a portion of the expandable retention structure. Optionally, one or more of the following features may further describe the drug releasing ureteral stent: a sleeve of drug releasing material is disposed on at least a portion of the expandable retention structure, optionally wherein the sleeve is a biodisintegrable sleeve, and / or the sleeve is a heat shrinkable sleeve, and / or the sleeve has an inner diameter in the range of 1-4 mm, a length in the range of 2-500 mm, and a thickness in the range of 50-200 micrometers; the stent includes a sheet of drug releasing material attached to the expandable retention structure, optionally wherein the sheet is a biodisintegrable sheet, and / or the sheet is an elastic sheet, and / or the sheet has a width in the range of 2-20 mm, a length in the range of 2-500 mm, and a thickness in the range of 50-200 micrometers; the stent includes a coil or loop. the stent includes a retention structure in the form of a coil or loop, where the sheet of drug releasing material occupies a majority of the coil or loop area upon deployment of the retention structure; the stent includes a sheet of drug releasing material connected to a sleeve of material located on at least a portion of the expandable retention structure; the stent includes a retention structure that is a renal retention structure configured to be delivered via the ureter and deployed within the kidney, optionally wherein the retention structure is adapted to be reduced to a profile small enough to allow the retention structure to be delivered to the kidney upon deployment; the stent has a retention structure including a plurality of elongated members having a sheet of drug releasing material attached thereto and between which the sheet of drug releasing material occupies upon deployment of the retention structure; the stent body and the expandable retention structure include a biostable polymer.
[0062] The loading of the drug in the polymer can be about 0-20 percent by weight of the device, depending on the nature of the material, the amount of polymer, the release profile of the polymer, the release profile of the drug, the desired drug diffusion effect, and the desired duration of drug delivery, among other factors. In one embodiment, the loading of the drug is about 1-10 percent by weight of the device.
[0063] Materials may be added to the polymer composition to specifically affect the release of the drug from the polymer. Such materials include, but are not limited to, styrene ethylene-butylene-styrene (SIBS), collagen, alginate, carboxymethylcellulose (CMC), hydroxypropylcellulose (HPC), dextrin, plasticizers, lipophilic materials and other fatty acid salts, pore formers, sugars, glucose, starch, hyaluronic acid (HA), chelating agents including ethylenediaminetetraacetic acid (EDTA), polyethylene glycol (PEG), polyethylene oxide (PEO), and copolymers thereof. To achieve a desired drug release profile, materials with different release profiles can be blended into the drug-containing polymer composition.
[0064] In one aspect, the present disclosure provides a bioabsorbable medical implant at least partially covered by an external containment layer, where the containment layer is non-bioabsorbable or at least partially bioabsorbable but does not degrade as rapidly as the medical implant. In one embodiment, in vivo, the medical implant degrades into fragments, but the external layer retains sufficient structural integrity to provide a barrier that the fragments from the implant cannot cross. In this way, these fragments are constrained to remain in a localized area where they cannot cause any harm to the host. In fact, even as the fragments degrade, the resulting smaller fragments and ultimately the molecular components of the implant all remain within the external containment layer and are guided together to a safe location for excretion.
[0065] Optionally, the containment layer and the degraded medical device are expelled at the same time. Both the medical device and the containment layer can be soft and compliant and can move along the vessel in which they are implanted, e.g., the ureter, until they are expelled from the host at the same time. The containment layer can be degradable, but it does not have to be. As long as the containment layer is soft and pliable and maintains its integrity, it can be expelled from the host at the same time the medical device is expelled.
[0066] The containment layer may help manage the segmentation of the device, i.e., the breakdown of the device into pieces. The containment layer may, for example, be placed in regions of the device to protect those regions from contact with the host's body fluids. The unprotected regions may degrade more quickly, resulting in cracks or segments in the medical device. The containment layer may be porous, thus allowing a controlled amount of the host's surrounding body fluids to contact the medical device. By adjusting the porosity of the containment layer, the segmentation of the device may be managed. Alternatively, by using a gradient coating, the parts of the medical device that are covered with relatively thin (less coated) areas will crumble into segments first. Alternatively, the medical device may be pre-degraded, for example, by exposing selected parts of the device to moisture for a period of time. These pre-selected regions may degrade earlier than other parts of the medical device. In this case, the containment layer may be located in the pre-degraded regions to control when those regions are exposed to the host's body fluids.
[0067] While the containment layer may be present on the exterior of the medical device, in another embodiment, the containment layer is disposed on the interior of the medical device, for example, on the interior of a medical device having a hollow space, i.e., a lumen. An exemplary medical device having a lumen is a stent. If the containment layer is disposed on the interior of the stent and the stent is biodegradable, fragments of the stent that form upon stent degradation will be retained between the containment layer and the host tissue for a sufficient time such that the fragments are manageably small, i.e., they are not large enough to be harmful to the host, or the fragments will degrade into their component polymeric or monomeric components and migrate through the containment layer.
[0068] gradient In one aspect, the medical device is characterized as having a gradient. A gradient refers to the variation of some property, e.g., the composition of a medical device, as a function of direction. This gradient provides a variation in degradation along the gradient. For example, the average molecular weight of the polymer forming the medical device may be varied along the direction of the medical device such that the polymer at the distal end of the medical device or a portion thereof has a higher average molecular weight than the polymer at the proximal end of the medical device or a portion thereof. In this way, the proximal end of the medical device or a portion thereof may degrade more quickly than the distal end where the polymer has a higher initial average molecular weight. The provision of a gradient in the medical device of the present disclosure provides a mechanism for the controlled degradation of the device. In one embodiment, the gradient does not affect or have no effect on the functionality of the medical device, but only affects the degradation profile of the device. Such heterogeneity of the medical device may be referred to herein as a gradient of the medical device, and a medical device having such a gradient may be referred to as a graded medical device.
[0069] Optionally, the containment layers of the present disclosure can be characterized as having a gradient such that the containment layer over one portion of a medical device is different from the containment layer over another portion of the medical device, such non-uniformity in the containment layer is referred to herein as a containment layer gradient, and a containment layer having such a gradient can be referred to as a graded containment layer.
[0070] For example, in one embodiment, the gradient provides for different degradation rates. The gradient may be constructed such that a containment layer covering one portion of a medical device degrades at a different rate, either faster or slower, than a containment layer covering a different portion of the medical device.
[0071] As another example, in another embodiment, the gradient provides a different degree of degradation. Thus, the gradient may be constructed such that a containment layer covering one portion of a medical device degrades to a different degree than a containment layer covering a different portion of the medical device. The degree of degradation may be measured in a variety of ways. For example, the thickness of the containment layer may be measured before implantation and then after it has been implanted and degraded to the maximum extent that it degrades. The change in thickness may be described as a percentage reduction in thickness, where the gradient provides a different percentage reduction in thickness in one portion of the medical device, either greater or less than the reduction in thickness that occurs in a different portion of the medical device.
[0072] As yet another example, in one embodiment, the gradient provides different sized pores in the containment layer at different locations, or optionally pores in some locations and no pores in other locations of the containment layer. In other words, the containment layer may have a variation in porosity. Thus, the gradient may be constructed such that the containment layer in one portion of the medical device is a mesh, net, knit, or other construct that includes pores, while the containment layer in a different portion of the medical device is solid, i.e., does not have any pores. Alternatively, the gradient may be constructed such that the containment layer in one portion of the medical device is in the form of a mesh or the like having relatively large pores, while the containment layer in a different portion of the medical device is also in the form of a mesh or the like, but with relatively small pores.
[0073] The gradient can be formed in a variety of ways. For example, different compositions having different degradation rates may be used to form the containment layer in different portions of the medical device. Thus, a composition having a relatively high degradation rate may be disposed in a first portion of the medical device, and a composition having a relatively slow degradation rate may be disposed in a second portion of the medical device. In this way, the containment layer will degrade more rapidly in some locations than in other locations.
[0074] As another example, a single composition may be used to form a graded containment layer. For example, a single composition may be coated to a first thickness on a first portion of a medical device, and the same composition is used to produce a coating having a second thickness on a second portion of the medical device. In general, a thicker coating will remain on the medical device longer than a thinner coating, or in other words, a thicker coating will degrade slower than a thinner coating, all other factors being equal. A thicker coating may be formed, for example, by repeatedly coating areas of the containment layer where a greater coating thickness is desired.
[0075] The thickness of the containment layer may vary throughout the medical implant. However, at its thickest point, in various embodiments, the containment layer has a thickness of greater than 10 microns, or greater than 20 microns, or greater than 30 microns, or greater than 40 microns, or greater than 50 microns, or greater than 60 microns, or greater than 70 microns, or greater than 80 microns, or greater than 90 microns, or greater than 100 microns, or greater than 110 microns, or greater than 120 microns, or greater than 130 microns, or greater than 140 microns, or greater than 150 microns, or greater than 160 microns, or greater than 170 microns, or greater than 180 microns, or greater than 190 microns, or greater than 200 microns. The maximum thickness may be 500 microns, or 400 microns, or 300 microns, or 200 microns, or 150 microns, or 100 microns. As previously mentioned, the containment layer may be a coating, where the thickness of the coating at its thickest point is any of the aforementioned thicknesses.
[0076] The amount of containment layer may vary throughout the medical implant. In one embodiment, in addition to or instead of specifying the thickness of the containment layer, the containment layer may also be characterized in terms of how much organic polymer is present for a given volume of medical device. For example, the amount may be expressed as the number of organic polymers per square centimeter (cm) of medical device. 2 ) in the medical device. In various embodiments, the medical device has a molecular weight of at least 10 mg / cm 2 or at least 15 mg / cm 2 or at least 20 mg / cm 2 or at least 25 mg / cm 2 or at least 30 mg / cm 2 or at least 35 mg / cm 2 or at least 40 mg / cm 2 or at least 45 mg / cm 2 or at least 50 mg / cm 2is covered with a containment layer in an amount of 100 μm.
[0077] As yet another example, the filaments forming the knit can be tightly or loosely knit to affect the number and size of holes in the knit. The containment layer may be constructed from two or more different knits that provide larger pores in a first portion of the medical device and smaller pores in a second portion of the medical device. In this manner, the containment layer allows the underlying medical device to degrade more rapidly in the first portion of the medical device (where the mesh pore size is larger and therefore the mesh allows surrounding bodily fluids to have greater access to the medical device) and more slowly in the second portion of the medical device (where the mesh pore size is smaller).
[0078] Thus, in one embodiment, the present disclosure provides a medical implant comprising a medical device and a graded containment layer covering at least a portion of the medical device. Optionally, the graded containment layer may comprise different thicknesses at different locations, e.g., 2, 3, 4, 5, or more than 5 thicknesses. A graded containment layer having multiple thicknesses at different locations can be formed by having different numbers of coating layers of a polymer composition at different locations, and thus can be said to comprise multiple layers (of a coating composition). Also, optionally, the graded containment layer may comprise multiple compositions at different locations, e.g., 2, 3, 4, 5, or more than 5 compositions. Optionally, the graded containment layer may comprise variations in two or more properties, e.g., multiple thicknesses and multiple compositions.
[0079] While thickness, composition, and porosity are examples of variations that may be present in the containment layer, these are merely examples, and other variations can also be used to create a graded containment layer in accordance with the present disclosure, such as variations in texture, variations in hydrophilicity, variations in thermal stability, variations in tensile strength, and, if the containment layer contains fibers, variations in fiber density, to name a few.
[0080] In one embodiment, the containment layer is made from one or more organic polymers. The containment layer may be completely non-biodegradable. However, in another embodiment, the containment layer is biodegradable, but it degrades at a slower rate than the medical device. Thus, if the medical device degrades into fragments, the containment layer maintains its structural integrity and holds the fragments together in the containment space for a sufficient time for the fragments to degrade into smaller fragments that are not harmful to the host and / or into the polymeric and / or monomeric components of the medical device.
[0081] In one embodiment, the containment layer is a coating on the medical device. This coating may be present on all exposed surfaces of the medical device or only on some of those surfaces, such as the sides. The coating may be completely non-biodegradable. However, in another embodiment, the coating is biodegradable, but it degrades at a slower rate than the medical device. In this way, if the medical device degrades into fragments, the coating maintains its structural integrity and holds the fragments together in the containment space for a sufficient time for them to degrade into smaller fragments that are not harmful to the host and / or into the polymeric and / or monomeric components of the medical device.
[0082] In particular, if the coating is biodegradable and the medical device breaks down into fragments, the coating must maintain sufficient strength over the period of disintegration of the medical device so that the coating can contain the fragments within the coating. To provide this function, the coating must be of sufficient thickness. To provide a coating of sufficient thickness, the medical device may be dipped into a polymer solution, i.e., a solution of dissolved polymer. The device may be dipped into the solution multiple times to build up a thickness of polymer that maintains sufficient strength and integrity to act as a containment layer during the disintegration of the medical device. Alternatively, the medical device may be dipped into the polymer solution. The speed at which the device is dipped into the solution affects the thickness of the coating, with slower dipping rates providing a thicker coating.
[0083] When a polymer solution is used to form a coating on a medical device, the concentration of the polymer in the solution is also a factor that must be considered: a higher concentration of polymer will tend to deposit more polymer on the surface of the medical device when the device is dipped, dipped, or otherwise coated with the polymer to form a containment layer.
[0084] The containment layer is placed on the portion of the medical device where it is desired to protect the host from injury or damage or trauma caused by fragments of the device that are formed during biodegradation. For example, in the case of a stent that is implanted into a host, when the stent is implanted partly into the host's kidney and partly outside the kidney, it is desirable that fragments of the disintegrating stent do not disperse into the kidney and cause kidney stones. Thus, the portion of the stent that is implanted into the kidney may be coated, but the portion of the stent that is implanted outside the kidney may not be coated. Thus, the containment layer is only present on the portion of the medical device.
[0085] The present disclosure shows that a containment layer can be provided for any medical device that degrades by a disintegration process, i.e., by a process in which the device breaks down into fragments. An exemplary device of this type is an intraureteral stent. The stent is initially biodegradable and disintegrable to maintain optimal ureteral patency for a period of time. At the end of this period, however, the stent begins to disintegrate into smaller fragments. To prevent migration of those smaller fragments, the stent is at least partially enveloped by a containment layer. This layer retains sufficient integrity so that the containment layer contains the smaller fragments for a period of time during which the smaller fragments are formed and then degrade into harmless fragments or degrade into their polymeric or molecular components. Thus, the containment layer serves to protect the host from the smaller fragments that are formed upon disintegration of the stent. The containment layer also protects the host from contact with the tough fragments that cannot be easily delivered outside the body.
[0086] Optionally, the device may not break down into smaller pieces, but instead soften sufficiently to allow it to pass through the conduit in which it is implanted, for example the ureter.
[0087] In one embodiment, the present disclosure provides a ureteral stent having diverse properties at different locations of the stent, but where the stent and its parts are not assembled from multiple segments. Rather, the stent is assembled from a single uniform construct, which is then modified to provide diverse properties at different locations of the construct. The diversity can be one or more properties including biodegradability, radiopacity, stiffness or flexibility, and loading with therapeutic agents. The diversity is created by methods as disclosed herein, for example, by slitting the parts of the stent to selectively degrade the stent or its parts before it is implanted in a host, and other methods as disclosed herein.
[0088] In one embodiment, the medical device is a stent that is a construction of fiber-reinforced elastomeric film designed with at least one position-retaining end, in which the fiber reinforcement is (a) a combination of monofilament coils and weft-knitted tubular multifilament yarns; (b) a combination of monofilament coils and braided multifilament yarns; (c) a tube comprising braided or weft-knitted monofilament yarns; or (d) weft-knitted or braided monofilament yarns in the form of a tube.
[0089] In yet another embodiment, the stent is a construction of a fiber-reinforced elastomeric film designed with at least one position-maintaining end, where the fiber reinforcement is a combination of monofilament and knitted or braided multifilament yarns, and the fiber-reinforced elastomeric film is in the form of a tube having a central main part having a diameter smaller than the patient's ureter, and each of the position-maintaining ends defines two freely laterally deformable parts consisting of initially partially overlapping bitubular ends of the main central part and laterally fused tubes that are radially and axially cut to create two overexpansion flaps attached to a complete semi-cylindrical extension of the main central tube.
[0090] In yet another embodiment, the stent is a construction of fiber-reinforced elastomeric film designed with at least one position-maintaining end, where the fiber reinforcement is a monofilament yarn or a combination with knitted or braided multifilament yarn, and the fiber-reinforced elastomeric film is in the form of a tube having a diameter smaller than the patient's ureter and having at least one position-maintaining end, which is an angled portion of the main tube having a length comparable to the patient's ureter and including a flexible joint that is free of deformation stress and maintains an angle of greater than 30° relative to the main tube.
[0091] In another embodiment, the stent includes a retention portion configured to help retain the stent in a proper position within the patient's body and an extension portion extending from the retention portion, the extension portion having a sidewall defining a lumen, the sidewall having a first section and a second section, the first section of the sidewall having a first thickness and the second section of the sidewall having a second thickness different from the first thickness. Optionally, the stent may be further characterized by one or more of the following: the retention portion is configured to be positioned within the patient's kidney; the retention portion is a first retention portion and the stent further includes a second retention portion configured to help retain the stent in a proper position within the patient's body; the first section of the sidewall forms an annular ring; the first section of the sidewall forms a helix; the first section of the sidewall forms a recess; the sidewall has a third portion and the second portion of the sidewall is disposed between the first portion of the sidewall and the third portion of the sidewall; the sidewall has a third portion, the third portion has a thickness different from the second thickness, and the second portion of the sidewall is disposed between the first portion of the sidewall and the third portion of the sidewall; the sidewall has a third portion, the second portion of the sidewall is disposed between the first portion of the sidewall and the third portion of the sidewall, and the third portion has a third thickness, the second thickness being greater than the first thickness, and the second thickness being greater than the third thickness; the first portion of the sidewall has a first section and a second section, and the first section of the first section forms a helix that rotates in a first direction, and the second section of the first section forms a helix that rotates in a second direction that is different from the first direction. The stent, including optional embodiments thereof, can be modified by the techniques disclosed herein to exhibit controlled degradation when the stent is placed in a host. For example, slits can be made into the slits to provide sites that promote degradation.
[0092] In another embodiment, the stent includes a retention portion configured to help retain the stent in a proper position within the patient's body and an extension portion extending from the retention portion, the extension portion having a first member and a second member, the first member lacking a lumen, the second member lacking a lumen, and the first member and the second member being interwoven. In another embodiment, the stent includes a retention portion configured to help retain the stent in a proper position within the patient's body and an extension portion extending from the retention portion and having an expanded configuration and a nominal configuration, the extension portion having a sidewall defining a lumen extending from a first end of the extension portion to a second end of the extension portion, the sidewall defining a chamber, the chamber configured to receive a fluid to place the extension portion in its expanded configuration. Again, any of these stents may be modified by the techniques disclosed herein to exhibit localized, controlled degradation within a host.
[0093] In another embodiment, the stent is a fiber-reinforced elastomeric film construct designed with at least one position-maintaining end, where the fiber reinforcement is a combination of monofilament and knitted or braided multifilament yarns, and the fiber-reinforced film is tubular having a diameter smaller than the patient's ureter and having a central main part that includes at least one position-maintaining end, where the position-maintaining end is a flexible extension of the central main tube that adopts a goose-neck shape after insertion into the patient's ureter, but can be collinear with the central main tube during insertion with an applicator.
[0094] In another embodiment, a stent includes an elongated member having a first portion and a second portion, the second portion having a sidewall defining a single lumen, the first portion coupled to the second portion, the first portion configured to be positioned within a kidney of a patient, the sidewall of the second portion of the elongated member configured to deliver fluid from a first location on the sidewall of the second portion to a second location on the sidewall of the second portion via at least one of capillary action and wicking, the second portion of the elongated member configured to be positioned within at least one of a bladder of a patient and a ureter of a patient, and at least a portion of the first portion disposed within the lumen. Optionally, the stent may be further characterized by one or more of the following features: the second portion of the extension member is constructed from a multi-strand material; the second portion of the extension member is constructed from yarn; the second portion of the extension member has a configuration selected from the group consisting of a braided tube configuration and a long woven strip configuration; the second portion of the extension member is constructed from melt spun polypropylene having a high barium sulfate loading; the stent further includes a proximal retention structure configured to be positioned within a patient's bladder, the proximal retention structure being coupled to the second portion of the extension member; the stent further includes a distal retention structure configured to be positioned within the kidney of the patent, the distal retention structure being coupled to the first portion of the extension member; the first portion being coupled to the second portion via an interference fit; the second portion of the extension member has a substantially solid tubular shape; the second portion of the extension member is substantially flexible; the first portion of the extension member is substantially rigid; the second portion of the extension member is more flexible than the first portion of the extension member. This stent, including its optional embodiments, may be modified in accordance with the present disclosure to exhibit controlled degradation.
[0095] In another embodiment, the medical device is a ureteral stent including an elongate member having a first portion and a second portion, the second portion having a substantially solid cylindrical shape, the first portion coupled to the second portion, the first portion configured to be disposed within a kidney of a patient, the first portion having a length such that the first portion terminates in at least one of the patient's kidney and a ureter, the second portion of the elongate member configured to deliver fluid from a first location of the second portion to a second location of the second portion via at least one of capillary action and wicking, the second portion of the elongate member configured to be disposed within at least one of the patient's bladder and the patient's ureter. This stent may be modified to exhibit managed degradation in accordance with the present disclosure.
[0096] In another embodiment, the stent contains at least one fibril, where the fibril has a longitudinal axis and is formed from a material comprising a bioabsorbable polymer material. The polymer molecules in the bioabsorbable polymer material may have a helical orientation that is aligned with the longitudinal axis of the fibril. The stent is at least partially bioabsorbed by the patient upon implantation or insertion of the stent into the patient. For example, the stent may include a braided or woven configuration; flared ends at the proximal or distal end of the stent; and at least one fibril having a longitudinal axis and comprising an oriented bioabsorbable polymer material, where the polymer molecules in the bioabsorbable polymer material have a helical orientation that is aligned with the longitudinal axis of the at least one fibril.Optionally, the stent may be further described as one or more of the following: the proximal and distal ends include flared ends; at least one filament is helically wound along at least a portion of the length of the stent; the stent comprises a plurality of filaments, optionally, the plurality of filaments is helically wound along at least a portion of the length of the stent, and further optionally, a first portion of the plurality of filaments is helically wound in a first direction and a second portion of the plurality of filaments is helically wound in a direction opposite the first direction. the plurality of fibrils are braided and helically wound along at least a portion of the length of the stent; the stent comprises stainless steel or nitinol fibrils; the stent comprises 12-36 helical fibrils; optionally 6-18 fibrils are in the form of helices axially displaced relative to each other, the helices extending in a first direction and an equal number of fibrils including helices extending in a second direction opposite the first direction, the fibrils being uniformly disposed along the longitudinal axis of the stent; the oriented bioabsorbable polymer material comprises a polymer selected from poly(α-hydroxy acid) homopolymers, poly(α-hydroxy acid) copolymers, and blends thereof; the oriented bioabsorbable polymer material comprises a polymer selected from polyglycolide, poly-L-lactide, poly-D-lactide, poly-DL-lactide, and blends thereof; the oriented bioabsorbable polymer material has a crystallinity in the range of 0.1-20%; at least one fine the fibers include a core of oriented bioabsorbable polymer material; at least one of the microfibers includes a coating of oriented bioabsorbable polymer material; the stent includes a plurality of oriented microfibers arranged to form a pattern of geometric diamond shaped cells; the plurality of microfibers are wrapped around one another to form interconnects; at least one of the microfibers includes a therapeutic agent; and the stent is selected from a coronary vascular stent, a peripheral vascular stent, a urethral stent, a ureteral stent, a biliary stent, a tracheal stent, a gastrointestinal stent, and an esophageal stent.
[0097] Another optional embodiment provides a stent that is a construction of fiber-reinforced elastomeric film designed with at least one position-retaining end, where the fiber reinforcement is a combination of monofilament yarn or knitted or braided multifilament yarn, where the fiber-reinforced elastomeric film is in the form of a tube with at least one position-retaining end that is an inverted cone having a cross-sectional diameter larger than the cross-section of the main tube and that can be reversibly compressed to match the diameter of the main tube (which is also smaller than the diameter of the patient's ureter) upon application of a radial compression force in an applicator. To facilitate radial compression during insertion with an applicator, the inverted cone is preferably partially slit to provide a cone wall with at least two leaflets, preferably three to four leaflets.
[0098] Yet another optional embodiment provides a fiber reinforced elastomeric film construct designed with at least one position maintaining end, where the fiber reinforcement is a combination of monofilament and knitted or braided multifilament yarns, the elastomeric film is tubular having a central main section with a diameter smaller than the diameter of the patient's ureter and with at least one position maintaining end, the position maintaining end being an asymmetric inverted cone with a teardrop shaped cross section, axially slitted at the tip of the teardrop with a larger cross sectional average diameter exceeding the cross section of the central main tube, the slitted asymmetric cone being reversibly compressible to match the central main tube diameter upon application of a radial compressive force within the applicator.
[0099] In yet another optional embodiment, the stent is a construction of fiber-reinforced elastomeric film, the fiber reinforcement being a combination of monofilament yarns or knitted or braided multifilament yarns, the reinforced elastomeric film being tubular with a central main part that is a one-sided longitudinally crimped inflatable tube having a circular cross-section smaller than the cross-section of the patient's ureter when deployed externally and having at least one position-maintaining end, where the position-maintaining end is a one-sided crimped inflatable asymmetric inverted cone having a teardrop-shaped cross-sectional geometry and a crimp at the tip of the teardrop that is collinear with the crimp of the central main tube, where the average diameter of the inverted cone when deployed externally exceeds the average diameter of the central main tube.
[0100] Optionally, the fiber-reinforced elastomeric film is formed from a segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group represented by l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholine-dione, p-dioxanone, and 1,5-dioxapan-2-one. Optionally, the film is formed from a mixture of ε-caprolactone and glycolide. Optionally, the film is formed from a mixture of L-lactide and glycolide. An exemplary composition of the elastomeric swellable film composition is a crystalline copolymer of high molecular weight (20-35 kDa) polyethylene glycol (PEG) and a 95 / 5 (molar) mixture of ε-caprolactone / glycolide, where the weight percent of the PEG component in the copolymer is about 10 percent.
[0101] Another exemplary composition of the elastomeric film composition is a crystalline segmented copolymer made in two stages. The first stage involves the formation of an amorphous or low melting copolymer made from ε-caprolactone, trimethylene carbonate and glycolide by polymerization in the presence of triethanolamine and stannous octoate as initiator and catalyst, respectively. In the second stage, the product of the first stage is reacted with a mixture of l-lactide and ε-caprolactone to produce the final crystalline triaxial copolymer.
[0102] Optionally, the film may be made from electrospun fibers. Optionally, the fiber-reinforced film may also include or contain monofilament yarns, optionally in combination with knitted or braided multifilament yarns, where the reinforcing monofilament yarns are formed from a segmented copolymer made from at least two cyclic monomers selected from the group represented by l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholine-dione, p-dioxanone, and 1,5-dioxapan-2-one. Optionally, the reinforcing monofilament yarns are formed from l-lactide, ε-caprolactone, and trimethylene carbonate, which are relatively slow degrading compositions. Optionally, the reinforcing monofilament yarns are formed from glycolide, ε-caprolactone, and trimethylene carbonate, which are relatively fast degrading compositions.
[0103] The reinforcing monofilament yarn may also be a composite of an inorganic particulate dispersed phase of at least one material selected from barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.Furthermore, the reinforcing monofilament yarn may be a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.
[0104] In yet another optional embodiment, the present disclosure provides a bioabsorbable and disintegrable, multi-component, non-migrating intraureteral stent that is a construction of fiber-reinforced elastomeric film designed with at least one position-retaining end, where the fiber reinforcement is a combination of monofilament yarns or knitted multifilament or braided yarns, and the reinforced knitted or braided multifilament fabric is formed from a crystalline segmented copolymer. An exemplary composition of such a copolymer is a triaxial copolymer that is produced in two stages. The first stage involves the formation of an amorphous or low melting triaxial prepolymer with ε-caprolactone and / or trimethylene carbonate in the presence of trimethylolpropane and stannous octoate as initiator and catalyst, respectively. In the second stage, the product of the first stage is reacted with glycolide or a mixture of glycolide and ε-caprolactone and / or trimethylene carbonate. Another exemplary composition is a copolymer for use in producing knitted or braided multifilament yarns, namely a crystalline copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group represented by l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholine-dione, p-dioxanone, and 1,5-dioxapan-2-one, preferably from polyethylene glycol, l-lactide, and trimethylene carbonate, more preferably a segmented copolymer of l-lactide and trimethylene carbonate. Optionally, the copolymer is made from glycolide and trimethylene carbonate, which provides a relatively rapid degradation profile for the yarn.
[0105] Thus, in one embodiment, the present invention provides an absorbable and disintegrable, multi-piece, non-migrating intraureteral stent that is a construction of a fiber-reinforced elastomeric film designed with at least one position-retaining edge, where the fiber reinforcement is a combination of monofilament coils and braided multifilament yarns, and the film is formed from a crystalline segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. The film may also be formed from a crystalline segmented copolymer made from l-lactide and at least one cyclic monomer selected from the group consisting of glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and 1,5-dioxepan-2-one, and morpholinedione.
[0106] The present disclosure further provides an absorbable and disintegrable, multi-component, non-migrating intraureteral stent that is a construction of fiber reinforced elastomeric film designed with at least one position-retaining end, where the fiber reinforcement is a combination of monofilament coils and braided multifilament yarns, and the reinforcing monofilament yarns are formed from a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, and 1,5-dioxepan-2-one. Alternatively, the reinforcing monofilament yarn is a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. The reinforcing monofilament yarn may also be a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.
[0107] Thus, the present disclosure also provides an optional embodiment that is an absorbable and disintegrable multi-piece, non-migrating intraureteral stent that is a construction of fiber-reinforced elastomeric film designed with at least one position-retaining edge, the fiber reinforcement being a combination of monofilament coils and braided multifilament yarns, the reinforced braided multifilament fabric being formed from a crystalline segmented copolymer made of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, trimethylene carbonate, ε-caprolactone, glycolide, p-dioxanone, morpholinedione, and 1,5-dioxepan-2-one, or the reinforced braided multifilament tube being formed from a crystalline segmented copolymer of l-lactide and at least one cyclic monomer selected from the group consisting of glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.
[0108] In another embodiment, the disclosure provides that the stent is a construction of fiber reinforced elastomeric film designed with at least one position maintaining end, where the fiber reinforcement is a tube of braided or weft knitted monofilament yarn, the fiber reinforced film is tubular with a central main part having a diameter smaller than the diameter of the patient's ureter and at least one position maintaining end, the position maintaining end being a flexible extension of the central main tube that assumes a loop shape with an open end parallel to the axis of the central main tube after insertion into the patient's ureter, the loop being capable of being collinear with the central main tube during insertion with an applicator. The film component of the assembled stent is formed from a crystalline segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. Alternatively, the film is formed from a crystalline segmented copolymer made from morpholinedione and at least one cyclic monomer selected from the group consisting of l-lactide and glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and 1,5-dioxepan-2-one.
[0109] In another embodiment, the present disclosure provides that the stent is a fiber-reinforced elastomeric film construction designed with at least one position-retaining edge, where the fiber reinforcement is a tube of braided or weft-knitted monofilament yarn, where the reinforcing braid or weft-knitted monofilament yarn is formed from a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, and 1,5-dioxepan-2-one. Alternatively, the reinforcing braid or weft-knitted monofilament yarn is formed from a crystalline segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, trimethylene carbonate, ε-caprolactone, glycolide, p-dioxanone, morpholinedione, and 1,5-dioxepan-2-one. The reinforcing weft knitted or braided monofilament may also be a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.Furthermore, the reinforcing weft knitted or braided monofilament may be a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.
[0110] Optionally, the stent is a fiber reinforced elastomeric film construct designed with at least one position-maintaining end, where the fiber reinforcement is a weft-knitted or braided monofilament scaffold, the reinforced construct therefrom being in the form of a tube including a central main section having a diameter smaller than that of the patient's ureter and at least one position-maintaining end, where the position-maintaining end is an inverted cone having a series of diameters designed to provide cross sections progressively larger than that of the central main tube and capable of being reversibly compressed to radially match the central main tube upon application of a radial compressive force upon insertion into the urogenital tract with a tubular applicator, and the film is formed from a crystalline segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. Alternatively, the film is formed from a crystalline segmented copolymer made from at least one cyclic monomer selected from the group consisting of l-lactide and glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and 1,5-dioxepan-2-one and morpholinedione. The reinforcing weft knitted or braided monofilament yarn may optionally be formed from a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, and 1,5-dioxepan-2-one. Alternatively, the reinforcing braided or weft knit monofilament yarn is formed from a crystalline segmented copolymer made from polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, trimethylene carbonate, ε-caprolactone, glycolide, p-dioxanone, morpholinedione, and 1,5 dioxepan-2-one.
[0111] In another optional embodiment, the stent is a fiber reinforced elastomeric film construct designed with at least one position-maintaining end, where the fiber reinforcement is a weft-knitted or braided monofilament scaffold, the resulting reinforced construct being in the form of a tube including a central main section having a diameter smaller than the diameter of the patient's ureter and at least one position-maintaining end, the position-maintaining end having a series of diameters designed to provide cross sections that are incrementally larger than the cross section of the central main tube, and that are adapted to compress the urogenital tract during insertion with a tubular applicator. It is an inverted cone that can be reversibly compressed to radially fit with a central main tube, where the reinforcing weft-knitted or braided monofilament yarn is a composite of an inorganic particulate dispersed phase of at least one material selected from the group of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer made from at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. Alternatively, the reinforcing braided or weft knit monofilament yarn is a composite of an inorganic particulate dispersed phase of at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass, and an absorbable polymer matrix of a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione.
[0112] In another embodiment, the present disclosure provides an absorbable and disintegrable, multi-piece, non-migrating intraureteral stent that is a construction of a fiber reinforced elastomeric film designed with at least one position-maintaining end, where the fiber reinforcement is a weft-knitted monofilament yarn, the reinforcement construction is in the form of a tube having a central main part with a diameter smaller than that of the patient's ureter and at least one position-maintaining end, where the position-maintaining end is a flexible extension of the central main tube that assumes a loop shape with an open end parallel to the axis of the central main tube after insertion into the patient's ureter, the loop being capable of becoming collinear with the central main tube during insertion with an applicator, the film being formed from a crystalline segmented elastomeric high l-lactide copolymer, the monofilament being formed from a segmented l-lactide copolymer with at least one cyclic monomer selected from the group consisting of glycolide, ε-caprolactone, and morpholinedione, and the monofilament containing a particulate inorganic filler selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass.
[0113] In one embodiment, the medical device is a stent having a longitudinal axis and comprising fibrils comprising oriented bioabsorbable polymer material, where the polymer molecules within the bioabsorbable polymer material have a helical orientation that is aligned with respect to the longitudinal axis of the fibrils, and where the stent is at least partially bioabsorbed by the patient upon implantation or insertion of the stent into the patient. In optional embodiments, one or more of the following features may further characterize the medical device: a) the fibrils are spirally wound along at least a portion of the length of the stent; b) the stent comprises a plurality of said fibrils, optionally wherein the plurality of fibrils are spirally wound along at least a portion of the length of the stent, optionally wherein a first direction of the plurality of fibrils is spirally wound and the plurality of fibrils is spirally wound in an opposite direction; c) the fibrils are braided fibrils, wherein the plurality of braided fibrils are braided and spirally wound along at least a portion of the length of the stent; d) the fibrils are knitted fibrils; e) the plurality of fibrils are knitted fibrils, wherein the oriented bioabsorbable polymer material is a single bioabsorbable polymer material. f) the oriented bioabsorbable polymeric material comprises a polymer selected from poly(α-hydroxy acid) homopolymers, poly(α-hydroxy acid) copolymers, and blends thereof; g) the oriented bioabsorbable polymeric material comprises a polymer selected from polyglycolide, poly-L-lactide, poly-D-lactide, poly-DL-lactide, and blends thereof; h) the oriented bioabsorbable polymeric material has a crystallinity in the range of 0.1-20%; i) the microfibrils comprise a core of oriented bioabsorbable polymeric material; j) the stent is selected from coronary vascular stents, peripheral vascular stents, urethral stents, ureteral stents, biliary stents, tracheal stents, gastrointestinal stents, and esophageal stents.
[0114] Optionally, the stent can remain patent and remain at the application site for at least 2 days, or 2-3 weeks, or degraded after 7 weeks, or degraded after 90 days, or degraded after 4 months.
[0115] The present disclosure provides the following further exemplary embodiments:
[0116] In one embodiment, the medical device is a biodegradable intraureteral stent. The stent includes a tubular elastomeric film and a tubular fiber reinforcement, where the tubular elastomeric film is a single tube covering the tubular fiber reinforcement. The stent has at least one position-maintaining end and a central main tube having a diameter smaller than the diameter of the patient's ureter, where the at least one position-maintaining end is an extension of the central main tube. The stent is configured to be placed in the patient's ureter and extend from the patient's kidney to the patient's bladder and be held in place by the at least one position-maintaining end. The film reinforces and impregnates the fiber reinforcement, where the fiber reinforcement includes a monofilament coil disposed in a knitted or braided tube of monofilament or multifilament yarn. The film and the fiber reinforcement each include an absorbable crystalline segmented copolymer including at least one cyclic monomer. The film and the fiber reinforcement alone are capable of maintaining ureteral patency.
[0117] The following options may further define the stent: a) at least one position-maintaining end is a flexible extension of the central main tube that assumes a goose-neck shape after insertion into the patient's ureter, but may be collinear with the central main tube during insertion with an applicator; b) the tubular elastomeric film is a flexible elastomeric film comprising polyethylene glycol and at least one selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. c) the tubular elastomeric film comprises a crystalline segmented copolymer of l-lactide and at least one cyclic monomer selected from the group consisting of l-lactide and glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and 1,5-dioxepan-2-one; d) the monofilament coil comprises a crystalline segmented copolymer of l-lactide and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, and 1,5-dioxepan-2-one. e) the monofilament coil comprises a composite comprising a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass; f) the monofilament coil comprises a composite comprising a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass;g) the monofilament coil comprises a composite material including a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione; h) the fiber reinforcement material comprises a monofilament coil and a multifilament coil. and a braided tube of laminar yarns, wherein optionally, 1) the tubular elastomeric film comprises a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione; and 2) the tubular elastomeric film comprises a crystalline segmented copolymer of l-lactone and glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and morpholinedione. 3) the monofilament coil comprises a crystalline segmented copolymer of at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, 1,5-dioxepan-2-one; 4) the monofilament coil comprises a composite comprising a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer of at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbent phosphate glass;5) The monofilament coil comprises a composite material including a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix being a crystalline segmented copolymer of polyethylene glycol and at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass. 6) the multifilament yarn comprises a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, trimethylene carbonate, ε-caprolactone, glycolide, p-dioxanone, morpholinedione, and 1,5-dioxepan-2-one; 7) the multifilament yarn comprises a crystalline segmented copolymer of l-lactide and at least one cyclic monomer selected from the group consisting of glycolide, ε-caprolactone, trimethylene carbonate, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione. j) the monofilament coil is disposed in a tube of weft knitted monofilament yarn, wherein optionally, 1) the tubular elastomeric film comprises a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione; , a crystalline segmented copolymer of l-lactide and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, p-dioxanone, and 1,5-dioxepan-2-one, and morpholinedione; 3) the monofilament yarn comprises a crystalline segmented copolymer of at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, morpholinedione, p-dioxanone, and 1,5-dioxepan-2-one;4) the monofilament yarn comprises a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, trimethylene carbonate, ε-caprolactone, glycolide, p-dioxanone, morpholinedione, and 1,5-dioxepan-2-one; 5) the monofilament yarn comprises a composite including a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer of at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbent phosphate glass; and 6) the monofilament yarn comprises a composite including a polymer matrix and an inorganic particulate dispersed phase contained within the matrix, the matrix comprising a crystalline segmented copolymer of at least two cyclic monomers selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbent phosphate glass. and an inorganic particulate dispersed phase contained within a matrix of the matrix comprising a crystalline segmented copolymer of polyethylene glycol and at least one cyclic monomer selected from the group consisting of l-lactide, ε-caprolactone, trimethylene carbonate, glycolide, p-dioxanone, 1,5-dioxepan-2-one, and morpholinedione, and an inorganic particulate dispersed phase comprising at least one material selected from the group consisting of barium sulfate, zirconium oxide, and absorbable phosphate glass; k) the stent remains patent and capable of remaining at the application site for at least 2 days; l) the stent remains patent and capable of remaining at the application site for 2-4 months; and m) at least one position retaining end contains at least 4% by weight of at least one powdered radiopaque agent selected from the group consisting of barium sulfate, zirconium oxide, and bismuth subcarbonate;
[0118] The following are some further embodiments of the present disclosure: 1) A medical implant comprising a containment layer at least partially encasing a medical device, the medical device being at least partially biodegradable when the implant is implanted in a host, the containment layer being either non-biodegradable or biodegradable, and wherein the containment layer acts as a container for the medical device when the medical device degrades in vivo. 2) The implant of embodiment 1, wherein the device provides structural support within the host. 3) The implant of embodiments 1-2, wherein the device is a stent. 4) The implant of embodiments 1 to 3, wherein the stent is an intraureteral stent. 5) The implant of embodiments 1-4, wherein the containment layer is a coating on the implant. 6) The implant of embodiment 5, wherein the coating is hydrophilic. 7) The implant of embodiments 5-6, wherein the coating is biodegradable, but the coating degrades slower than the medical device. 8) The implant of embodiments 5 to 7, wherein the coating has a thickness greater than 20 microns. 9) The implant of embodiments 5 to 8, wherein the coating has a thickness greater than 40 microns. 10) The implant of embodiments 5 to 9, wherein the coating has a thickness greater than 60 microns. 11) The implant of embodiments 5 to 10, wherein the coating has a thickness greater than 80 microns. 12) The implant of any one of embodiments 5 to 11, wherein the coating has a thickness greater than 100 microns. 13) The implant of embodiments 5 to 12, wherein the coating has a thickness greater than 120 microns. 14) A medical implant comprising a containment layer at least partially encapsulated by a medical device, wherein the containment layer at least partially encapsulates a hollow core of the medical device, wherein the medical device is at least partially biodegradable when the implant is implanted in a host, wherein the containment layer is either non-biodegradable or biodegradable, wherein the containment layer provides a barrier between degradation products that form during biodegradation of the medical device and the hollow space of the medical device.
[0119] It should be understood that the terminology used herein is for the purpose of describing particular embodiments only and is not intended to be limiting. It should also be understood that, unless specifically defined herein, the terminology used herein is to be given its conventional meaning as known in the relevant art.
[0120] The references herein to "one embodiment" or "an embodiment" and variations thereof mean that a particular feature, structure, or characteristic described with respect to that embodiment is included in at least one embodiment. Thus, the appearances of "in one embodiment" or "in an embodiment" in various places throughout this specification are not necessarily all referring to the same embodiment. Moreover, these particular features, structures, or characteristics may be combined in any suitable manner in one or more embodiments. Any of the medical device embodiments disclosed herein may include a drug, e.g., a therapeutic or prophylactic drug, as part of the medical device.
[0121] As used herein and in the appended claims, the singular forms "a," "an," and "the" include plural, i.e., one or more, referents, unless the content and context clearly dictate otherwise. It should also be noted that the conjunctions "and" and "or" are generally used in their broadest sense, including "and / or," unless the content and context clearly dictate the inclusion or exclusion, as the case may be. Thus, the use of alternatives (e.g., "or") should be understood to mean either one, both, or any combination of those alternatives. In addition, the compositions of "and" and "or" recited herein, when recited as "and / or," are intended to include certain embodiments including all of the associated items or concepts, and one or more other alternative embodiments including less than all of the associated items or concepts.
[0122] Unless the context requires otherwise, in this specification and the following claims, the word "comprise" and its synonyms and variations, such as "have" and "include," and variations thereof, such as "comprises" and "comprising," are to be interpreted in an open inclusive sense, such as "including but not limited to." The term "consisting essentially of" limits the claim to materials or steps specified or that do not materially affect the basic and novel characteristics of the claimed invention.
[0123] Any headings used herein are merely used to expedite the reader's review and should not be construed as limiting the scope of the invention or the claims in any way. Thus, the headings and abstracts of the disclosure provided herein are merely for convenience and do not interpret the scope or meaning of the embodiments.
[0124] Certain specific details are set forth herein to provide a thorough understanding of the various disclosed embodiments, however, one skilled in the art will recognize that the embodiments may be practiced without one or more of these specific details, or with other methods, components, materials, etc.
[0125] The examples and products shown below describe and illustrate the medical devices of the present invention and the methods of making such devices. It should be understood that the scope of the present invention is not limited in any way by the scope of the following examples and products. Indeed, unless the context indicates otherwise, when a particular polymer is used in the examples, this polymer is merely an example and may be substituted with another polymer in accordance with the present invention. Also, when degradation times and properties are exemplified, it should be understood that these values are approximate and other values would be obtained using different starting materials. The starting materials and various reactants used or referenced in the examples are available from commercial suppliers or are made from commercially available organic compounds using methods well known to those skilled in the art. Thus, the following examples are illustrative of embodiments of the present invention and should not be construed as limiting thereof. EXAMPLES
[0126] Example 1 Making a coil from MG5-B Assemble a 1-liter stainless steel kettle with a three-neck glass lid equipped with an overhead mechanical stirrer, a vacuum adapter, and a nitrogen inlet. The kettle is evacuated to a pressure of approximately 0.5 mmHg and then purged with nitrogen. Charge the kettle with 9.15 g of paxTMC-1, which has been pre-dried by heating to 220° C. PaxTMC-1 is made by combining trimethylene carbonate (TMC) and trimethylolpropane (TMP) in a 15:1 TMC:TMP molar ratio with heating and stirring in the presence of a tin catalyst such as stannous octoate. Also add glycolide (313.8 g, 2.705 mol), ε-caprolactone (132.1 g, 1.159 mol), and a radiopaque agent to the kettle. In one embodiment, the radiopaque agent is barium sulfate microparticles (245 g), having a diameter of 1 to 4 microns. The apparatus is submerged in an oil bath and the contents are placed under vacuum at 40°C for 1 hour, after which the system is purged with nitrogen. The temperature of the oil bath is increased to 95°C and the contents of the kettle are mixed thoroughly. After a homogeneous fluid composition is obtained, a 0.2 M solution of stannous octoate in toluene (2.576 mL, 5.152 x 10-4 moles stannous octoate) is added. The temperature of the oil bath is increased to 180°C where the polymerization reaction occurs and stirring is continued for as long as possible. If stirring is not possible (due to high viscosity), the reaction product is maintained at 180°C for 7 hours.
[0127] The kettle is allowed to cool to room temperature and then submerged in a cold bath to freeze the polymer. The frozen polymer is removed from the kettle and crushed. The crushed material is sieved to obtain a powder with the desired maximum particle size. The sieved powder is transferred to a 2 liter pear-shaped glass flask and placed in a Buchirota Vapor. After a vacuum of 0.25 mmHg is obtained, the flask is submerged in an oil bath and the temperature is increased to 40°C. After 2 hours at 40°C, the temperature of the oil bath is increased to 80°C, and after 1 hour at 80°C, the temperature is increased to 110°C. The temperature is maintained at 110°C for 4 hours.
[0128] The attributes, particle size and amount of the radiopaque agent can be selected to have a desired effect on the implant degradation profile. In general, a sufficient amount of radiopaque agent should be included in the composition to allow visualization of the composition. Excess radiopaque agent, i.e., an excess amount of radiopaque agent above that required for visualization, may be included in the composition to affect the degradation rate of the composition. Without intending to be bound by theory, it is believed that excess radiopaque agent creates stress points in the composition that promote degradation. For example, if at least 20 percent by weight of radio-opacifying agent must be present to visualize the implant, in various embodiments the present disclosure provides compositions containing at least 5%, or at least 10% (even 2 percent by weight), or at least 15%, or at least 20% (even 4 percent by weight), or at least 25%, or at least 30% (even 6 percent by weight), or at least 35%, or at least 40% (even 8 percent by weight), or at least 45%, or at least 50% (even 10 percent by weight), or at least 55%, or at least 60%, or at least 65%, or at least 70%, or at least 75% excess radio-opacifying agent.
[0129] In addition to selecting the amount of radiopaque agent, the particle size of the radiopaque agent can also be selected. Radiopaque agent particles of various particle sizes and particle size distributions are commercially available, for example, from Sigma-Aldrich, St. Louis MO. Radiopaque agents, such as barium sulfate, may have a nominal particle size of about 1.0 to about 20 microns. In embodiments, the radiopaque agents used in the medical devices of the present disclosure have a nominal particle size of at least 1.0, or 2.0, or 3.0, or 4.0, or 5.0, or 6.0, or 7.0, or 8.0, or 9.0, or 10.0, or 11.0, or 12.0, or 13.0, or 14.0, or 15.0, or 16.0, or 18.0, or 19.0, or 20.0, each value in microns. Optionally, the maximum particle size may be specified as 20.0, or 19.0, or 18.0, or 17.0, or 16.0, or 15.0, or 14.0, or 13.0, or 12.0, or 11.0, or 10.0, or 9.0, or 8.0, or 7.0, or 6.0, or 5.0, or 4.0, or 3.0, or 2.0, or 1.0, again in microns. In general, larger particles impart a faster degradation profile to the medical device, as they impart a greater stress concentration in the resulting fiber, leading to a faster degradation of tensile properties and ultimately to faster fragmentation. Also, a higher weight percentage of radiopaque agent particles contributes to a faster degradation profile.
[0130] Generally, lower concentrations of more dense radiopaque agents can be used. Barium sulfate has a density of 4.5 g / cm 3 and therefore generally more barium sulfate must be loaded into the medical device to achieve effective visualization compared to, for example, tantalum oxide, tungsten metal, and zirconium oxide, which are examples of radiopaque agents with a higher density than barium sulfate. Particulate forms of Bi2O2(CO3), i.e., bismuth subcarbonate, BiOCl, i.e., bismuth oxychloride, and Bi2O3, i.e., bismuth trioxide, are other radiopaque agents that may be incorporated into the medical devices of the present disclosure.
[0131] In one embodiment, the radiopaque agent is present during the polymerization process, while in another embodiment, the radiopaque agent is added to the preform polymer.
[0132] Example 2 Melt spinning and properties of radiopaque monofilament using MG5-B obtained from Example 1 and its processing into coil scaffold (CS) The polymer is extruded into monofilaments using a single screw extruder with four sections. For example, the polymer from Example 1 is extruded using a 0.6 mm die. 325 lines per inch of filter pack are used. Section 1 is maintained at 100°C, section 2 at 175°C, section 3 at 212°C, and section 4 / spin pack at 214°C. The metering pump is operated at 8 rpm and the take-up roll is set at 40-60 rpm. The collected monofilaments may have a diameter of 0.58 mm to 0.61 mm. The fibers are stretched 4.5 times in a first stage at 55°C and 0.5 times in a second stage at 70°C to a diameter of 0.30 mm to 0.33 mm. The free shrink is about 8.85% to 10.43% at 50°C. The fibers are relaxed to half the free shrinkage + 2% at 70°C. The resulting fibers can have a maximum load of about 13N and are dimensionally stable.
[0133] The processed radiopaque monofilament is then helically coiled around a 0.55" diameter Teflon cord that maintains the inner diameter of the coil scaffold. The monofilament is wrapped around the Teflon cord at 33-35 coils per inch.
[0134] Example 3 Synthesis and Characterization of Triaxially Segmented Glycolide Copolymer (MG-9) or Its Use in Fabricating Knitted Scaffolds A reaction apparatus was assembled containing a 1 L stainless steel kettle with a three-neck glass lid equipped with an overhead mechanical stirrer, a vacuum adapter, and a nitrogen inlet. After obtaining a vacuum of 0.5 mm Hg, the apparatus was purged with nitrogen. An initial charge of paxTMC-1 (16.0 g, as described in Example 1), ε-caprolactone (38.6 g, 0.3382 moles), and glycolide (745.4 g, 6.4262 moles) was added to the kettle. The apparatus was submerged in an oil bath. The kettle and contents were heated to 110° C. and mixed under positive nitrogen pressure. Once it was determined that the initiator was sufficiently dissolved in the monomer, a 0.2 M solution of stannous octoate in toluene (0.966 ml, 1.933×10 -4 mol) is added. The temperature is increased to 180°C. Stirring is stopped when the resulting polymer mixture becomes too viscous to stir. The reaction is maintained at 180°C for 5 hours. The polymer is frozen, removed and crushed. The crushed material is sieved. The sieved polymer is transferred to a 2 L pear-shaped glass flask and placed in a Buchirota Vapor. After a vacuum of 0.5 mm Hg is obtained, the flask is submerged in an oil bath. The temperature is increased to 40°C. After 2 hours at 40°C, the temperature of the oil bath is increased to 80°C. After 1 hour at 80°C, the temperature is increased to 110°C. The temperature is maintained at 110°C for 4 hours.
[0135] Example 4 Melt spinning and properties of multifilament yarn using MG-9 obtained from Example 3 and its processing into knitted scaffold (KS) The polymer is extruded into multifilaments using a single screw extruder with 5 zones. The polymer from Example 3 is extruded using a 20 hole die with 0.018" diameter holes. 400 lines per inch filter pack is used. Zone 1 is maintained at 190°C, Zone 2 is maintained at 210°C, Zone 3 is maintained at 222°C, Zone 4 / pump is maintained at 228°C, and Zone 5 / spin pack is maintained at 228°C. 0.584cc / rev The Zenith metering pump is operated at 6.0 rpm and the denier control roll is set at a line speed of 315 meters / min. The fiber is then oriented onto three high speed godets moving at 320, 465, and 480 M / min and heated to 60° C., 80° C., and 26° C., respectively. The recovered multifilaments are then reoriented at a temperature of 100° C. and at speeds of 250 M / min to 280 M / min. The resulting fiber may have a tenacity of 3.26 and a denier of 80.4. The processed multifilaments are then twisted once to create a 40 filament fiber, which is then weft knitted in a continuous fashion using a Ram circular knitter onto the coiled scaffold from Example 2. A 7 / 8″ knitting cylinder with 12 course gauge needles is used to form a knitted scaffold onto the coiled scaffold.
[0136] Example 5 Synthesis and characterization of triaxially segmented l-lactide copolymer (SVG-12) or its use as a reinforcing composite matrix (CM) Assemble the reaction apparatus including a 4 L stainless steel reactor equipped with an overhead mechanical stirrer, a vacuum adapter, and a nitrogen inlet. After a vacuum of less than 0.5 mm Hg is obtained, purge the apparatus with nitrogen. Heat the oil and circulate it through the jacketed reactor to control the temperature. Add glycolide (254.9 g, 2.1976 mol), trimethylene carbonate (348.7 g, 3.4185 mol), pre-dried triethanolamine (3.0319 g, 2.0348 x 10 -2 mol), stannous octanoate (354.5 mg, 8.752 × 10 -4An initial charge of 1,2-diol (974.3 g, 8.5463 moles) and ε-caprolactone (974.3 g, 8.5463 moles) is added to a 2 L flask and dried under high vacuum at 40° C. for 1.25 hours. The contents of the flask are then added to a 4 L reactor. The system is then purged with nitrogen. The oil temperature is increased to 175° C. and the contents are mixed well for 6.5 hours, then the temperature is reduced. Once mixed, a final charge of glycolide (226.6 g, 1.9534 moles) and l-lactide (1195.5 g, 8.3021 moles) is added. The oil temperature is then increased to 135° C. and maintained for 19 hours.
[0137] The resulting polymer is removed and dissolved in dichloromethane (DCM) at a concentration of 4 milliliters per gram so that the polymer is precipitated into isopropyl alcohol (IPA) at -60°C and any monomers remain soluble and can be rinsed away. The polymer is then dried to constant weight.
[0138] Example 6 Assembly of the composite ureteral stent construct Preparation of polymer matrix solution - SVG-12 from Example 5, polyethylene glycol (M W A polymer solution containing PEG 4600 (PEG 4600) and acetone is made by adding 1600 milliliters of acetone to one 64 ounce jar, followed by 16.0 grams of PEG 4600 and 144.0 grams of purified SVG-12. The solution is sealed and mild heat is used to aid in dissolution. The jar is placed on an autorotator until complete dissolution is achieved.
[0139] Continuous Impregnation of Knit Core - A dry knit core is impregnated with a polymer matrix of SVG-12 and PEG4600 using a continuous matrix impregnation process that involves continuously moving the knit core material through a 0.75 liter bath of polymer solution. From the start of the impregnation apparatus, the knit core is unspooled and immediately fed into a bath of polymer solution where two in-line dipping pulleys keep the scaffold material immersed for the length of the bath. As the impregnated material exits the bath, it passes through an air circulating drying tube heated to 40°C, then through a stainless steel member heated to 50°C, and then the impregnated material is wound onto a final take-up spool.
[0140] Forming of Impregnated Knit Cores - The impregnated material is wound around racks equipped with two parallel 0.5 inch diameter stainless steel bars whose separation distance can be adjusted to control the final stent length. The freshly impregnated knit cores are wound around these racks in a continuous fashion. The racks are annealed at 130°C for 30 minutes, after which the racks are allowed to cool to room temperature in a laminar flow hood. Multiple stents are removed from each rack by cutting the scaffold material at the appropriate location within the interior of the separating rods of the forming rack. These stents, which still contain the Teflon cores, are modified by adding a UVJ marker at the base of each stent, within 1 centimeter of what will eventually become the proximal loop of each stent. The proximal loops of all stents are then further coated by hand dipping each proximal loop into 150 milliliters of a 10% polymer solution of SVG-12 and PEG4600 in acetone (w / v; 9.3% SVG-12, 0.7% PEG4600). The stents are hung by the distal loop in a laminar flow hood to dry. The Teflon core is then removed from each stent by clamping one end of the Teflon core to a fixed-position vice-grip pliers (as the opposite end of the Teflon core is tensioned using a second set of vice-grip pliers). After a clean cut of the tensioned Teflon core at the fixed end, the reduced diameter Teflon core is pulled from the stent and discarded. Finally, each stent is trimmed to the appropriate specifications.
[0141] Example 7 Assembly of the composite ureteral stent construct Preparation of polymer solution. The polymer solution was prepared by mixing 16.0 grams of polyethylene glycol (PEG4600; M W A 100 ml solution of purified SVG-12 was made by combining 100 ml of ethanol (=4600), 1600 milliliters of acetone, and 144.0 grams of purified SVG-12 in a jar. The solution is sealed and mild heat is used to aid in dissolution. The jar is placed on an autorotator until complete dissolution is achieved.
[0142] The dry knit scaffold from Example 4 is impregnated with the polymer solution described above using a continuous impregnation method involving continuous transfer of the knit core material into a 0.75 liter tank of polymer solution. The scaffold is fed off of a spool and fed into a tank of coating solution where two in-line dipping pulleys keep the scaffold material submerged for the length of the tank. As the impregnated material leaves the tank, it is passed through an air circulating drying tube heated to 40°C, then through a stainless steel member heated to 50°C, and the impregnated material is then wound onto a final take-up spool. This process is repeated to obtain a thicker coating on the scaffold, the thicker coating having a smooth surface.
[0143] The impregnated knitted scaffolds are wound around racks equipped with two parallel 0.5 inch diameter stainless steel bars whose separation distance can be adjusted to control the final stent length. The freshly impregnated knitted scaffolds are wound around these racks in a continuous fashion. The racks are annealed at 130°C for 30 minutes, after which the racks are allowed to cool to room temperature in a laminar flow hood.
[0144] Several stents are removed from each rack by cutting the scaffold material at the appropriate locations within the separating rods of the forming rack. These stents, which still contain the Teflon core, are modified by adding a UVJ marker at the base of each stent, within 1 centimeter of what will eventually become the proximal loop of each stent.
[0145] The proximal loop of the stent is additionally coated using an MTS Synergie test instrument to mechanically immerse the proximal end of the stent into the coating solution using multiple cycles in a controlled manner. The distal end of the stent is attached to a vertical fixture of the MTS test instrument, which is programmed to immerse the stent into a 100 mL graduated cylinder containing 100 mL of coating solution. The program procedure lowers the stent into the cylinder to the 20 mL mark and immediately pulls the stent out of the cylinder. The MTS instrument pauses long enough to allow the coating to dry when the stent is suspended above the coating solution, approximately 30 to 300 seconds until it is tack-free, and then the immersion procedure is repeated, except that the stent is lowered to the 40 mL mark. The MTS program performs two final immersion cycles in which the stent is lowered to the 60 mL mark and then to the 80 mL mark. This results in an outer coating layer with a thickness gradient, with the thickest coating layer being located on the proximal loop. This ensures that the proximal loops are reinforced with more coating material than the rest of the stent to prevent premature degradation of the proximal loops.
[0146] The stents are hung by the distal loop in a laminar flow hood to dry. The Teflon™ PTFE core is then removed from each stent by clamping one end of the Teflon core to a fixed-position vice-grip pliers (as the opposite end of the Teflon is tensioned using a second set of vice-grip pliers). After a clean cut of the tensioned Teflon core at the fixed end, the reduced diameter Teflon core is pulled from the stent and discarded. Finally, each stent is trimmed to the appropriate specifications.
[0147] The resulting stent has a rapidly degrading inner structure (knitted scaffold) and a hydrophilic outer containment layer that degrades more slowly than the inner structure. The inner structure degrades and is completely eliminated within 4 days, or 1 week, or 2-4 weeks, or 2-7 weeks, or longer, such as 90 days, or longer, such as 6 months, while the longer lasting containment layer is still present after the inner structure is completely degraded such that the containment layer is present for at least 4 weeks before it degrades and is excreted. As a result, the containment layer serves to retain the inner structure and its degradation products until complete degradation and excretion occurs. This function of the containment layer prevents the ingress of the degradation products of the rapidly degrading material into the kidney, which may result in complications necessitating removal of the remaining material that may cause blockages, etc. This is one example of a containment layer that may be used in conjunction with a medical device, such as any of the medical devices disclosed herein, to provide a controlled degradation when the device is implanted in a host.
[0148] Example 8 Containment layers that may be used in conjunction with medical devices to provide controlled degradation This embodiment provides a bioabsorbable ureteral stent that includes an inner containment layer, an intermediate monofilament coil in a helical configuration, a weft-knit mesh on the exterior of the monofilament coil, and other three-component materials, specifically an outer hydrophilic containment layer applied as an outer layer that also penetrates and fills the void and void spaces between the intermediate coil and the weft-knit mesh components. The outer containment layer degrades slower than the monofilament coil and weft-knit mesh components, resulting in a containment layer that serves to retain the degradation products of the coils and mesh, which degrade within 2-4 weeks.
[0149] The first step in constructing a multi-component bioabsorbable ureteral stent involves applying an inner coating layer to a monofilament cord of polytetrafluoroethylene (PTFE) having a diameter of approximately 0.055 inches. The inner coating layer functions as an inner containment layer. The PTFE monofilament cord is coated according to the drawing method disclosed in Example 1, except that the PTFE monofilament cord is replaced with a knit core, a polymer solution of 15% (weight / volume) polymer in acetone is used, and the monofilament is coated twice using the procedure described. The monofilament is fed into the polymer solution at a speed not exceeding 6 meters per second (m / s) to ensure that the surface of the PTFE is coated with a polymer coating of sufficient thickness that the coating can function as a containment layer. This is one example of a containment layer that may be used in connection with a medical device, such as any of the medical devices disclosed herein, to provide for managed degradation when the device is implanted in a host.
[0150] Example 9 Caps that may be used in conjunction with medical devices to manage degradation A cap may be added to the stent, where the cap provides part or all of the containment layer. The caps are located at either end of the stent and bridge the open lumen of the stent to fill the capped ends of the stent.
[0151] A cap may be placed on a stent as illustrated herein. The cap is formed after removing the Teflon monofilament cord from the stent. After the cord is removed, the end of the stent is dipped into a solution of a degradable polymer. The solution is sufficiently viscous that after the stent is removed from the solution, a small amount of the solution bridges the open lumen at the end of the stent and leaves a polymer film covering the dipped end of the stent when the solvent is removed by evaporation. This polymer film is the cap. This process may be repeated several times as necessary to achieve the desired thickness for the cap.
[0152] Alternatively, the cap may be made of a degradable mesh that is attached to the end of the stent to form a cap. In this embodiment, the cap is porous, which may be desirable, for example, if the stent is a urethral stent. However, the cap need not be porous, or the cap may only become porous after it is implanted.
[0153] These are examples of caps that may be used in connection with a medical device, such as any of the medical devices disclosed herein, to provide for controlled degradation when the device is implanted in a host.
[0154] Example 10 Forming a longitudinal slit in a coil component to create a predictable breaking point in the coil component Glycolide copolymer (MG5-B) is made by melt extrusion into a stabilized monofilament and oriented to create a fiber of about 0.3 mm diameter, which is further processed via a coiling process on a 0.055" diameter Teflon cord to maintain the inner diameter of the coil. After coiling, while still on the Teflon cord, the coiled part is passed through a stationary knife edge cutter to impart a longitudinal slit approximately 0.02 mm deep transverse to the fiber axis and axially along the length of the coil. The longitudinal slit reduces the initial tensile strength by a small amount, e.g., about 5%. Tensile strength is measured by placing a segment of the monofilament into a tensile strength tester after removing the monofilament from the cord. The result of the cutting is a coiled slit scaffold with 33-35 coils per inch of glycolide copolymer monofilament and a transverse slit along the length of the scaffold. In vivo, the implant breaks along the slit points, with degradation occurring initially at the location of the slit.
[0155] The slit depth can be selected in terms of the diameter of the monofilament. In various embodiments, the slit depth can be 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 11%, 12%, 13%, 14%, 15%, 16%, 17%, 18%, 19%, 20%, 21%, 22%, 23%, 24%, 25%, 26%, 27%, 28%, 29%, 30%, 31%, 32%, 33%, 34%, or 35% of the diameter of the monofilament (including ranges selected from these percentage values).
[0156] This is an example of a slit that can be made in a medical device, such as any of the medical devices disclosed herein, to provide for controlled degradation when the device is implanted in a host.
[0157] Example 11 Fabrication of a degradable ureteral stent containing a longitudinal defect to provide a predictable degradative failure point Glycoprene polymer (made from 93% glycolide, 5% caprolactone, and 3% trimethylene carbonate) formed into multifilament fibers with a tenacity of 3.26 and a denier of 4.0 per microfiber is produced by a melt extrusion process. A Ram circular knitter is used to knit the glycoprene multifilament fibers in a continuous fashion onto the coiled slit scaffold from Example 10. A 7 / 8" knitting cylinder with 12 course gauge needles is used to form a knit scaffold onto the coiled slit scaffold.
[0158] In a separate container, add SVG-12, polyethylene glycol (M wA polymer solution containing PEG 4600 (PEG 4600) and acetone is made by adding 1600 mL of acetone to a 64-oz jar, followed by 16.0 grams of PEG 4600 and 144 grams of SVG-12. The solution is sealed and briefly heated to aid in dissolution. The jar is placed on an automatic rotator until complete dissolution is achieved. Continuous impregnation of the knit cores (all in this bath; even Teflon cores) is performed by moving the knit cores continuously through a 0.75 liter bath of polymer solution. From the start of the impregnation apparatus (consisting of a spool; a coating bath; and a collection spool), the knit cores are fed off the spool and immediately into the bath of polymer solution, where two in-line dipping pulleys keep the scaffold material immersed for the length of the bath. As the impregnated material leaves the tank, it is passed through an air circulating drying tube heated to 40°C, then through a stainless steel member heated to 50°C, and then collected on a final take-up spool and stored under vacuum to complete the drying process.
[0159] The stent is formed from the impregnated knit core by winding it onto a rack equipped with two parallel 0.5 inch diameter stainless steel bars whose separation distance can be adjusted to control the final stent length. Once on the forming rack, the structure is annealed at 130°C for 30 minutes and allowed to cool to room temperature in a laminar flow hood. The stent is cut from the forming rack to the final net shape of the degradable ureteral stent and the Teflon core is removed by clamping one end of the Teflon into a fixed position vice grip pliers (the opposite end is used to pull the Teflon core to reduce its diameter to allow removal from the stent length). Each stent produced by this method is inspected for appropriate specifications.
[0160] This coating and forming technique leaves a longitudinal slit created along the length of the inner coil, but is initially protected for the impregnation process. This is an example of a slit forming and coating technique that may be used in connection with a medical device, such as any of the medical devices disclosed herein, to provide for controlled degradation when the device is implanted in a host.
[0161] Example 12 In vitro hydrolysis of stents fabricated with longitudinal slitting of the coil components The impregnated and shaped degradable ureteral stent from Example 11 degrades primarily from hydrolysis of the main chain esters of the polymer backbone. As the stent reaches later stages of degradation, the MG5-B monofilament coil component has the ability to define the length of the fragments generated, but longer fragment lengths are more likely to partially or completely obstruct the ureteral sphincter, leading to transient incontinence. During in vitro hydrolysis of the impregnated and shaped degradable ureteral stent from Example 11, the longitudinal slits create defects that predispose to fracture at the slit sites. Upon incubation at 37° C. in artificial urine, the degradable stent initially loses strength along the entire length of the stent while maintaining a bulk morphology for the first approximately 5-7 days (compared to approximately 7-12 days without the slits). For the composition of the artificial urine, see ASTM F1828-97 (reapproved 2006), method of preparation A1.2.
[0162] Subsequent degradation, primarily within the MG5-B monofilament coil, reduces the tensile strength to approximately less than about 20% of the initial strength, creating a fragile monofilament that can break under mechanical input. The coil breaks first at the slits before fragmenting from the degradable ureteral stent. The fragments are 0.03 mm to 15 mm long, which then readily break into smaller segment lengths with stent migration. A degradable ureteral stent as described in Example 11 hydrolyzes within about 30 days of placement into segments suitable for migration from the genitourinary tract.
[0163] Example 13 Alternative mechanisms for creating defects to provide predictable coil failure points The defects that create the controlled degradation of the biodegradable medical implant can be provided in several ways. As previously exemplified, the monofilament in coiled form can be cut to provide a slit of a specific depth. The depth of the cut can be selected to have a desired effect on the fiber tensile strength, with increasing depth of the cut being positively correlated with increasing loss of tensile strength. If the depth of the cut exceeds 30% of the fiber diameter, the tensile strength can lose 50% or more from the initial strength, and the mechanical performance of the coil becomes less than that required to maintain ureteral patency. Thus, in one embodiment, the depth of the cut is less than 30% of the diameter of the coiled monofilament. Increasing the depth of the cut provides faster degradation of the coil portion of the stent, but this must be balanced against providing the strength retention time required for the functionality of the stent.
[0164] The cuts do not have to be uniform. Rather than in a continuous manner with each individual coil having one cut, shallow cuts of at least 0.03 mm may be made in an interrupted manner along the axis of the coil, for example. This may serve to create larger fragments of the stent during the degradation process, although stent fragments larger than 10 mm may not be desirable due to potential for occlusion.
[0165] Instead of making cuts in the coil with a knife edge cutter, other techniques may be used to destroy the coil portion of the medical device, for example, a laser may be used to create a slit by cutting 3-30% of the coil diameter from the stent without creating a large heat affected zone.
[0166] A laser may also, or instead, be used to provide a point energy source for the purpose of creating one or more regions of stress through disruption of the polymer crystalline structure, stressing within the coiled polymer, and degrading the polymer chain length (all to cause more rapid degradation). A combination of heating and laser ablation can also be used for combination reduction.
[0167] These are examples of creating defects in a medical device, such as the medical devices disclosed herein, to provide for controlled degradation when the device is implanted in a host.
[0168] Example 14 Selective removal of stent impregnated coating to create degradation sites Impregnated and formed degradable ureteral stents may be modified to facilitate degradation into smaller segments by selective removal of the impregnated coating along the length of the stent. Impregnated and formed stents may be fabricated by removing peripheral bands of the coating spaced apart, e.g., 1 cm apart, along the length of the shaft, i.e., along the central segment of the stent. This can be accomplished by applying a suitable solvent, such as acetone, to dissolve the impregnated coating in narrow bands of the desired width, e.g., approximately 1 mm wide, from the shaft around the entire circumference of the stent. This process exposes the treated segments of the knit and coil components of the stent. The resulting stent includes a continuous coil, e.g., formed from MG5-B, a continuous knit component that houses the coil, and the impregnated coating in segments along the length of the stent, e.g., 1 cm long, then spaced apart, e.g., 1 mm, before the next segment of the impregnated coating.
[0169] This illustrates a method of creating defects in a medical device that is applicable to any medical device, including any of the medical devices disclosed herein, to provide for controlled degradation when the device is implanted in a host.
[0170] Example 15 In vitro hydrolysis of degradable ureteral stents with sections of selectively removable impregnated coatings The impregnated coating of the stent essentially serves as a passivation layer to control the hydrolysis rate of the underlying coiled and knitted components. During hydrolysis of the stent produced in Example 14, the sections with the coating removed are less protected from degradation. In vitro hydrolysis of the stent obtained from Example 14 can be performed using artificial urine at 37°C. The sections of the stent with the impregnated coating selectively removed are expected to lose strength approximately 20% more rapidly than those with the coating, promoting the occurrence of fracture at those sites, thereby resulting in a degradation length of approximately 1 cm to allow easier clearance from the ureter and bladder without obstruction.
[0171] Example 16 Methods for creating preferred decomposition vectors by application of ionizing radiation The application of ionizing radiation can be used to reduce the molecular weight of synthetic bioabsorbable polyesters. In an attempt to create a favorable degradation vector or gradient within the stent, beta radiation can be applied in one direction, along the length of the stent, with a total exposure of about 10-50 kG on the bladder curl side of the stent, transitioning to about a 50% reduced radiation dose on the kidney curl side of the stent.
[0172] To generate this dose vector, a stent as described in Example 6 is placed in a metal foil pouch and dried under vacuum at room temperature to minimize residual moisture. The package is then sealed with a nitrogen atmosphere to provide protection from light and moisture. The bladder curled end is then encapsulated in a single layer straight into the sealed package containing the stent for processing.
[0173] The packaged stent is then subjected to electron beam irradiation, a process involving high energy beta radiation. This technique uses a cathode source to generate accelerated electrons that are shaped into a collimated beam. This process produces radiation that has a limited depth of penetration. By applying this technique to a stent-containing box oriented so that the bladder curl is closest to the radiation source, the bladder curl receives a high dose of radiation, with the effective applied dose fading along the length of the packaging, ultimately resulting in the kidney curl end of the stent getting approximately 60% of the radiation energy at the bladder curl end.
[0174] By creating a stent with a graded radiation dose, the degradation profile is tailored so that the stent breaks preferentially starting at the bladder curl and gradually moving towards the renal curl, thereby promoting small degradation products, which minimizes the risk of stent-induced incontinence.
[0175] Thus, the present disclosure provides a method for determining whether the device itself has a non-uniform molecular weight (M w Or M n The present disclosure also provides a method for making a medical device in which electron beam irradiation is applied in a non-uniform manner along the device to include a polymer having a gradually non-uniform polymer molecular weight (M w Or M n ) to provide a device with a change in
[0176] This illustrates a method of creating defects in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0177] Example 17 Method for producing preferred resolved vectors by adjusting coil pattern and coil density The primary mechanism for retaining shape during degradation is the presence of MG5-B coils within the stent. To create preferential degradation pathways, in one embodiment, the stent coils are tailored along the length of the stent shaft during coil fabrication. To achieve this result, a Teflon monofilament serves as a core to create and maintain the internal lumen of the stent during fabrication. MG5-B or other monofilament fibers are wound around the Teflon core to create the coil components of the stent. During coil fabrication, the sections of the coil that will ultimately become the bladder curl and kidney curl are created with a coil density of about 33-35 coils per inch. In the shaft region of the stent that forms the central section of the stent, the coils are created with a tailored coil density that progresses from about 33 to 35 coils per inch at the kidney curl transition to about 15 to 20 coils per inch at the bladder curl transition.
[0178] These coil densities may vary at the beginning, end, and along the shaft. For example, the shaft region of the stent may have a coil density of, for example, 30, or 31, or 32, or 33, or 35 coils / inch at one of the shafts (e.g., near the kidney-coil transition). The coil density may gradually decrease along the length of the shaft. For example, at the bladder-coil transition, the coil density may be only, for example, 12, or 13, or 14, or 15, or 16, or 17, or 18, or 19, or 20, or 21, or 22, or 23, or 24, or 25 coils / inch.
[0179] During in vitro degradation at 37°C in artificial urine, the segments of the stent shaft having 15-20 coils per inch lose strength to a level that supports stent rupture several days, e.g., 1, or 2, or 3, or 4, or 5 days earlier than the transition section closest to the kidney, providing a degradation vector from the bladder to the kidney. As the stent shaft begins to rupture in stages, the segments become separated from the stent shaft, providing a "bottom-up" degradation pathway, minimizing the risk of stent-induced incontinence.
[0180] This illustrates a method of creating degradation vectors in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0181] Example 18 An alternative method for creating preferred decomposition vectors by tailoring stent components. In further embodiments, other techniques may be used to create preferred decomposition vectors along the stent shaft.
[0182] Impregnation coatings may be applied by spray coating techniques onto the Teflon core of coils, such as MG5-B based coils, where the thickness applied varies along the length of the shaft. According to this approach, the impregnation coating thickness is applied at a level of 8% by weight of the total weight of MG5-B+glycoprene+SVG12 / PEG on both curls as well as the kidney curl transition, while at the bladder curl transition, the coating is applied at a level of 4% by weight, with a linear coating gradient between the bladder and kidney curls. With this approach, the integrity of the stent is first lost at the bladder end of the shaft.
[0183] In other embodiments, the impregnating coating thickness is applied at a level of 5%, 6%, 7%, 8%, 9%, 10%, 11%, or 12% by weight of the total weight of MG5-B+glycoprene+SVG12 / PEG on both curls as well as the kidney curl transition, while at the bladder curl transition the coating is applied at a lower level with a linear coating gradient between the bladder and kidney curls. For example, if the impregnating coating thickness is up to 12% by weight, the coating thickness may be gradually reduced to 11%, then 10%, then 9%, then 8%, etc., to the desired thickness, thus creating a coating thickness gradient.
[0184] These examples illustrate methods of creating degradation vectors in specific medical devices to provide for controlled degradation when the device is implanted in a host, and these approaches are applicable to any medical device, including any of the medical devices disclosed herein.
[0185] Example 19 An alternative method for creating preferred decomposition vectors by tailoring stent components. Another way to create a preferred degradation vector for a stent having coil, knit, and coating constructs as described above is to treat the surface of the device with plasma. Plasma treatment adds hydroxyl groups to the surface of the device, which mobilize more water when the device is implanted in a host, thereby promoting degradation of the surface. The plasma treatment can be selected such that some surfaces receive more plasma treatment than others, and therefore have more hydroxyl groups. In this way, a gradient of hydroxyl groups is created along the stent shaft, with the greatest level of exposure at the bladder curl transition, increasing local hydrophilicity and locally degrading / disintegrating the polymer, thereby promoting the initial strength loss closest to the bladder curl and progressing along the stent shaft to the kidney curl.
[0186] This chemical treatment to induce early degradation can be applied by other means as well, including acid treatment at various levels to induce chain scission and hydrophilicity. In addition, the spray coating composition can be tailored along the length of the stent by varying the ratio of PEG4,600 to SVG12, using higher concentrations of PEG4,600 at the bladder curl transition and lower concentrations at the kidney curl transition.
[0187] This illustrates a method of creating degradation vectors in a particular medical device to provide for managed degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein. Thus, the present disclosure provides a method of forming a stent, a method that includes constructing a stent from components including coils, knits, and coatings, and then subjecting the stent to a chemical treatment that induces premature degradation of the stent when it is implanted in a host.
[0188] Example 20 Design and Fabrication to Create a Layered Core-to-Sheath Disintegration Vector A degradable ureteral stent having an innermost coil fabricated from an overknit having a radiopaque, glycolide-based monofilament, then a glycolide-based multifilament, and then sheathed with a degradable polymer film, where the monofilament coil exhibits the fastest degradation profile, followed closely by the overknit multilament, and finally the film sheath, exhibiting the longest degradation lifespan.
[0189] A 0.3 mm diameter MG5-B monofilament coil is wound around a 0.055" diameter Teflon core at 33-35 coils per inch. A Ram circular flat knitter is used to knit the glycoprene multifilament in a continuous fashion onto the coiled and slit scaffold previously described. A 7 / 8" knitting cylinder with 12 course gauge needles is used to form a knitted scaffold onto the coiled scaffold. A 3 / 4" single barrel custom melt extruder is used with a tubing die heated to approximately 165°C to extrude the SVG-12 and polyethylene glycol blend as a thin sheath. The coiled and knitted Teflon assembly is passed through a tubing die head allowing for direct application of a tubular sheath.
[0190] Stents are formed from impregnated knit cores by winding them around a rack equipped with two parallel 0.5 inch diameter stainless steel bars whose separation distance can be adjusted to control the final stent length. Freshly impregnated knit cores are formed by winding them around these racks. Once on the forming rack, the structures are annealed at 130°C for 30 minutes and allowed to cool to room temperature in a laminar flow hood. The stents are cut from the forming rack to the final net shape of the degradable ureteral stent and the Teflon core is removed by fastening one end of the Teflon in a fixed position vice grip (the opposite end is used to pull the Teflon core to reduce its diameter to allow removal from the stent length). Each stent produced in this manner is inspected for appropriate specifications. In this manner, degradable ureteral stents can be made such that the SVG-12 and PEG sheaths remain as distinct layers that maintain the outer stent diameter but do not individually coat the MG5-B coil or glycoprene knit.
[0191] During in vitro degradation in artificial urine at 37°C, the MG5-B coil loses strength in approximately 7-14 days, after which it fragments and readily migrates away from the remaining glycoprene fibers and outer sheath. As the coil, and subsequently the knit, fragments, they may detach from the remaining stent and deposit in the bladder, further degrading into smaller fragments before excretion by artificial urination. Similarly, the SVG-12 / PEG sheath may also collect in the bladder and fragment before excretion by artificial urination.
[0192] This illustrates a method of creating degradation vectors in specific components of a medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0193] Example 21 Inclusion of multiple coils to control the rate of coil separation The polydioxanone polymer is melt extruded as a monofilament using a 3 / 4" single screw extruder and then oriented and heat treated to create a 0.3 mm diameter thermally stable strong monofilament. The MG5-B stabilized monofilament fiber is coiled in a continuous fashion using a Ram circular knitter onto a 0.055" diameter monofilament Teflon core. In another 15 cm section, the polydioxanone monofilament is co-coiled with the MG5-B monofilament to provide a second coil component. In both sections of the coil (with and without polydioxanone monofilament), the net coil density remains constant at 33-35 coils per inch. The resulting coil is processed as a finished degradable ureteral stent as described in Example 6 to form a stent with a MG5-B only coil from approximately the midpoint of the shaft to the bladder curl. The portion of the stent between the midpoint of the shaft and the tip of the renal curl contains coils of both MG5-B and polydioxanone monofilament.
[0194] During in vitro degradation in artificial urine at 37°C, the section of the stent below the midpoint of the shaft breaks off and separates from the main stent body first. The MG5-B coil in the renal half of the stent is retained within the stent due to the extended strength retention of the second coil component. After 14 days, when the MG5-B has significantly degraded and fragmented, the polydioxanone coil begins to fragment, releasing the particulate MG5-B, residual coating and knitted components, eventually allowing migration of the residual polydioxanone coil to the bladder. These fragments are further degraded in the bladder until they are expelled by artificial urination.
[0195] Thus, the present disclosure provides a medical device comprising two different polymers, each having a unique degradation profile (i.e., the two polymers have different degradation profiles from each other), where the two polymers are each used to make the same part of the medical device. In this example, the same part is the coil of a stent. Thus, the coil part of the stent is fabricated from two coils, where the two coils comprise different polymers with different degradation profiles.
[0196] Example 22 Manufacturing alternatives for producing discontinuous decomposition particles: Monofilament diameter adjustment The coil component of a degradable ureteral stent is generally the primary feature for providing structural support for the stent as well as the primary strength mechanism for maintaining luminal patency when implanted. To promote degradation of the monofilament into discontinuous particles, the coil material, e.g., MG5-B, is melt extruded as a continuous monofilament and oriented in a pulsed fashion at 2x and 5.5x draw ratios with a period of 5mm such that the resulting fiber exhibits diameters of 0.3mm at the peaks and 0.2mm at the valleys. These diameter values are merely examples: other non-identical diameter values can be produced using pulsed extrusion. The monofilament is then processed by winding at a coil density of 33-35 coils per inch onto a Teflon core having a 0.055" diameter. The coil is further processed as described in Example 6 to form a degradable ureteral stent.
[0197] During in vitro degradation in artificial urine at 37° C., MG5-B monofilaments of various diameters degrade preferentially at the smallest diameter segment of the monofilament, resulting in MG5-B particles approximately 5 mm long.
[0198] This illustrates a method of creating heterogeneity in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device having fibrils, including any of the medical devices disclosed herein that contain fibrils.
[0199] Example 23 Manufacturing alternatives for producing discontinuous decomposition particles: Embossed Monofilament MG5-B monofilament is melt extruded and oriented to a uniform diameter. In a second process, the monofilament is passed through a rotary embossing machine equipped with a recessed pattern at 2-10 mm increments to create stress concentrations and physical defects along the length of the fiber. The embossed monofilament is then wound onto a Teflon core with a 0.055" diameter at a coil density of 33-35 coils per inch and further processed as described in Example 6 to form a degradable ureteral stent.
[0200] During in vitro degradation in artificial urine at 37° C., the embossed monofilament degrades preferentially at the locations of the embossed recesses, resulting in MG5-B particles approximately 5 mm in length.
[0201] This illustrates a method of creating defects in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0202] Example 24 Manufacturing alternatives for producing discontinuous decomposition particles: Heat Treatment The MG5-B monofilament is melt extruded and oriented to a uniform diameter. In a second process, the monofilament is partially heat treated in 2 mm segments along the fiber axis to reduce the crystalline orientation of the MG5-B monofilament. The partially heat treated monofilament is then wound onto a Teflon core with a 0.055" diameter at a coil density of 33-35 coils per inch and further processed as described in Example 6 to form a degradable ureteral stent.
[0203] During in vitro degradation at 37° C. in artificial urine, the partially heat-treated monofilaments degrade preferentially at the site of heat treatment, yielding MG5-B particles approximately 2 mm in length.
[0204] This illustrates a method of creating defects in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0205] Example 25 Manufacturing alternatives for producing discontinuous decomposition particles: Annular Support The MG5-B polymer is injection molded as an open ring structure (clip) with an internal lumen diameter of 0.050" and a wall thickness of 0.3 mm. The coils are further designed so that the "top" and "bottom" of the clip have flat features for improved stacking, handling during downstream processing, and aiding in buckling resistance during stent insertion. These clips are placed onto a Teflon core with a 0.055" diameter in a spatial arrangement of 30-35 clips per inch and held in place by frictional forces. The Teflon core containing the MG5-B clips is further processed as described in Example 6 to form a degradable ureteral stent.
[0206] During in vitro degradation in artificial urine at 37° C., the injection molded clips separate due to degradation in the knit and coating layers, resulting in discrete particles less than 0.3 mm thick.
[0207] This illustrates a method of creating defects in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0208] Example 26 Manufacturing alternatives for producing discontinuous decomposition particles: Sea Island MG5-B and 85:15 PLGA are co-extruded in an islands-in-the-sea monofilament configuration with 1-10 fibrils of 85:15 PLGA at 5 denier per fibril, with "islands" in the "sea" of MG5-B. The monofilaments are oriented to increase tensile strength and heat stabilized to optimize thermal stability. The attenuated monofilaments are wound around a Teflon core with a 0.055" diameter in a spacing of 33-35 coils per inch. The coiled Teflon core is further processed as described in Example 6 to form a degradable ureteral stent.
[0209] During in vitro degradation at 37°C in artificial urine, the MG5-B component of the coil loses strength prior to the 85:15 PLGA "islands" that help maintain the initial coil structure of the stent until the MG5-B component degrades into fragments smaller than 0.5 mm. Once the MG5-B component of the coil is separated from the "islands," the fibrils generally aggregate into small, loosely packed structures that allow for easy elimination from the bladder with urination.
[0210] This illustrates a method of creating defects in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0211] Example 27 Manufacturing alternatives for producing discontinuous decomposition particles: Monofilament Shape The MG5-B polymer was melt extruded using a single screw 3 / 4" extruder with a multi-lobe die having multiple fins emanating from a central hub, resulting in a melt flow rate of approximately 0.07 mm. 2 After orientation and heat treatment, the monofilament is coiled onto a 0.055" Teflon core at a density of 33-35 coils per inch to form the stent coil.
[0212] This illustrates a method of creating asymmetric parts in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0213] Example 28 Alternative monofilament shapes To control degradation morphology, the MG5-B polymer may be melt extruded into various non-circular cross-sectional shapes. For example, the polymer may be melt extruded into a bilobal monofilament with a narrow central section to induce degradation primarily into two separate longitudinal lengths to increase compliance of the degradation by-products. Alternatively, the polymer may be melt extruded into a flattened monofilament or tube to promote degradation of the coil component into smaller particles while maintaining bending stiffness and maintaining stent mechanics.
[0214] This illustrates a method of creating asymmetric parts in a particular medical device to provide for controlled degradation when the device is implanted in a host, and this approach is applicable to any medical device, including any of the medical devices disclosed herein.
[0215] Example 29 Inclusion of buffers to neutralize the acidity of degradation by-products Degradable ureteral stents are fabricated using the modified coating solution as described in Example 6. The coating solution is made using SVG-12, polyethylene glycol (Mw=4,600), and finely divided sodium dihydrogen phosphate (e.g., 5% by weight) dissolved and dispersed in acetone. The resulting degradable ureteral stent impregnated coating contains approximately 0.5-3% by weight of sodium dihydrogen phosphate. After implantation, the sodium dihydrogen phosphate is released from the coating and helps buffer urine against the effects of acidic degradation by-products to maintain typical urinary pH levels of 6.5-8.0.
[0216] Example 30 Inclusion of antispasmodics to counteract the irritation induced by foreign substances A degradable ureteral stent is prepared using a modified coating solution as described in Example 6. The coating solution is prepared using SVG-12, polyethylene glycol (Mw=4,600), and an antispasmodic drug such as atropine dissolved and dispersed in acetone. The resulting degradable ureteral stent impregnated coating contains at least 0.5 mg of atropine. After implantation, atropine is released from the impregnated coating and serves to control spasms in the ureter and urethra, which may be caused by the presence of the foreign body or its degradation products, through its anticholinergic effect.
[0217] Example 31 Stent surface features for improved placement stability A degradable ureteral stent is fabricated as described in Example 6 using a barbed monofilament fiber with a diameter of 0.3 mm as the coil component. The resulting stent exhibits a barbed surface feature that serves to penetrate after deployment to reduce the risk of stent migration. Optionally, the stent is fabricated without a bladder curl, as the presence of the barbed on the stent surface maintains stability in the deployment location. Optionally, the bladder curl may be replaced with a flaring section to prevent the stent from migrating upward into the kidney.
[0218] Example 32 Further manufacturing approaches for forming degradable ureteral stents Additional manufacturing approaches will be used to continuously create different degradation pathways, including surface features for placement stability. A Stratasys J750 Polyjet printer will be utilized to deposit three different materials to provide components of the final stent structure as described.
[0219] Component 1 is a rapidly degradable glycolide-based photocurable resin loaded with an inorganic radiopaque agent and is used as the radial stiffening element and is printed into the body of the stent as a coil.
[0220] Component 2 is a rapidly degradable poly(propylene fumarate) photocurable resin that is contained axially throughout the shaft of the stent to act as a reinforcing member for deployment and potential activation.
[0221] Component 3 is a flexible trimethylene carbonate-based light-curable resin that is included as a tissue interface coating to form the stent sheath, bond with components 1 and 2, and maintain the net-stent configuration.
[0222] Component 1 is included within the stent such that the orientation and shape of the coil structure provides a flat inner lumen and a textured outer surface to increase friction between the ureteral wall and the stent surface for improved placement stability.
[0223] Tailoring the thickness of component 3 within the stent can provide faster degradation in specific locations to create defects that rupture 1-3 days sooner than those coated with more component 3. Additionally, component 3 is designed to create a porous (discontinuous) film barrier if desired.
[0224] Component 2 is included to maintain the continuity of the stent and is included as an axial component in an interrupted fashion to allow fracturing and separation of the stent segments at specific sites.
[0225] The net stent shape, including both the bladder curl and the kidney curl, is produced in a single process without the need for additional curing or heat treatment. The stents are washed in an isopropanol bath at 37° C. for 1 hour to remove residual photoinitiator and unreacted reagents prior to drying, packaging and sterilization.
[0226] During in vitro degradation at 37°C in artificial urine, fragmentation occurs preferentially in areas lacking component 3. Stent connectivity is maintained by component 2, but in the event of coil rupture, stent integrity is maintained within the stent structure until coil rupture occurs upon interruption of component 2. This rupture allows a small section of the stent to escape into the bladder where it is excreted with urination.
[0227] Example 33 Coil component elastic modulus USD polymers are made by ring-opening polymerization of polydioxanone and PEG macromonomer (Mw=10,000) to form semi-crystalline polymers with melting points between 100-120° C. The USD polymers are isolated, ground, and sieved to obtain a granule size of 1-4 mm, and devolitalized to remove residual monomer.
[0228] The USD polymer is melt extruded as monofilaments using a 3 / 4" single screw extruder. The monofilaments are oriented 2x to 5.5x and annealed at 80°C to enhance thermal stability. Fiber tensile testing confirms a tensile modulus of approximately 500-800 MPa, approximately twice the modulus of MG5-B monofilaments. The USD monofilaments are coiled on a 0.055" Teflon core at a coil density of 30-40 coils / inch, or 33-35 coils per inch. The coiled monofilaments are fabricated into degradable ureteral stents as described in Example 6.
[0229] During in vitro degradation in artificial urine at 37°C, the polyether component of the USD monofilament coils results in the coils breaking down and fragmenting over a period of approximately 10-21 days, allowing the remaining stent fragments to migrate into the bladder. Due to the higher modulus of USD monofilament compared to MG5-B monofilament, the coil fragments tend to retain their coiled shape, preventing other stent components from collapsing and forming a dense mass, which may help reduce the risk of incontinence and / or blockage within the urethra.
[0230] Example 34 Inherently Radiopaque Polymers Coating polymer RS-1 is synthesized using 33% ε-caprolactone, 32% l-lactide, 17% glycolide, 14% trimethylene carbonate with 4% 3-iodo-1-propanol as initiator. Stannous octoate is used as catalyst. The polymer is isolated, dissolved in dichloromethane, precipitated in cold isopropanol to remove impurities, and then dried before analysis and storage.
[0231] Degradable ureteral stents are produced by first creating a coiled construct using MG5-B as described in Example 1 without a radiopaque additive. Glycoprene multifilament fibers are weft knitted into a coil component. RS-1 is dissolved in acetone and the coil / knit component is coated by successive dip coatings to create a coated scaffold. The coated scaffold is formed into a stent net shape as described in Example 6.
[0232] Coatings made from RS-1 are inherently radiopaque as a result of the iodine content in the polymer, creating a stent that can be visualized by X-ray after implantation. Unlike other disclosed stent structures described in the above examples that contain solid inorganic particles as a radiopaque agent, the stent of this example does not contain solid inorganic particulates. As the stent degrades in vivo, the absence of inorganic particulates minimizes the inflammatory response that can result from the high hardness of the particulates.
[0233] Although any methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present invention, a limited number of exemplary methods and materials are described herein. In general, unless otherwise specified, materials for manufacturing the present invention and / or components thereof may be selected from any suitable material, such as biodegradable polymers.
[0234] Where a range of values is given herein, unless the context clearly indicates otherwise, it is understood that each intervening value, to the tenth of the unit of the lower limit, between the upper and lower limits of that range, and any other stated or intervening values of that stated range, are encompassed within the invention. The upper and lower limits of these smaller ranges may be independently included, and subject to any specifically excluded limit in the stated range, the smaller ranges are also encompassed within the invention. Where the stated range includes one or both of the limits, ranges excluding either or both of those included limits are also included in the invention.
[0235] For example, any concentration range, percentage range, ratio range, or integer range recited herein should be understood to include the integer values within the recited range, and fractions thereof (tenths and hundredths of integers), where appropriate, unless otherwise indicated. Also, any numerical range recited herein for physical characteristics such as polymer subunits, size, or thickness should be understood to include any integer within the recited range, unless otherwise indicated. As used herein, the term "about" means ±20% of the recited range, value, or structure, unless otherwise indicated.
[0236] All publications and patents cited herein are incorporated by reference in their entirety for the purpose of describing and disclosing, for example, materials and methods described in the publications that might be used in connection with the presently described invention. The publications discussed above and herein are provided solely for their disclosure prior to the filing date of the present application. Nothing herein should be construed as an admission that the inventors are not entitled to antedate any of the referenced publications by virtue of prior invention.
Claims
1. A method of forming a stent comprising constructing a stent from components including a coil, a knit, and a coating, and then subjecting the stent to a chemical treatment to induce premature degradation of the stent when implanted in a host.
2. 1. A medical implant comprising a containment layer at least partially encasing a medical device, said medical device being at least partially biodegradable when said implant is implanted into a host, said containment layer being either non-biodegradable or biodegradable, wherein said containment layer functions as a container for said medical device when the medical device degrades in vivo.
3. The implant of claim 2 , wherein the device provides structural support within a host.
4. The implant of claim 3 , wherein the device is a stent.
5. The implant of claim 4 , wherein the stent is an intraureteral stent.
6. The implant of claim 2 , wherein the containment layer is a coating on the implant.
7. The implant of claim 6 , wherein the coating is hydrophilic.
8. The implant of claim 6 , wherein the coating is biodegradable, but the coating degrades slower than the medical device.
9. The implant of claim 6 , wherein the coating has a thickness greater than 20 microns.
10. The implant of claim 6 , wherein the coating has a thickness greater than 40 microns.
11. The implant of claim 6 , wherein the coating has a thickness greater than 60 microns.
12. 7. The implant of claim 6, wherein the coating has a thickness greater than 80 microns.
13. The implant of claim 6 , wherein the coating has a thickness greater than 100 microns.
14. The implant of claim 6 , wherein the coating has a thickness greater than 120 microns.
15. 1. A medical implant comprising a containment layer at least partially encapsulated by a medical device, wherein the containment layer at least partially encapsulates a hollow core of the medical device, the medical device being at least partially biodegradable when the implant is implanted into a host, the containment layer being either non-biodegradable or biodegradable, and wherein the containment layer provides a barrier between degradation products that form during biodegradation of the medical device and the hollow space of the medical device.
Citation Information
Patent Citations
Braided bifurcated and trifurcated stents and method of making same
JP2002535076A
Fiber Reinforced Composite Absorbable Endoureteral Stent
JP2008529597A
degradable implantable medical device
JP2008534232A
Biodegradable internal artificial organ and method for manufacturing the same
JP2010503494A
A medical device having a biodegradable polymer region and a rigid, thin layer covering the biodegradable polymer region.
JP2010504152A
